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CHAPTER I 
 
INTRODUCTION 
 
 In this introductory chapter, I primarily focus on excitatory transmission and 
neural networks linked to addiction and stress.  I first consider addiction, the addictive 
process, methods to study this process, neuronal networks and their interactions, with an 
emphasis on long-lasting neuroadaptations (excitatory synaptic plasticity) persisting long 
after drug intake.  Also conditions such as stress and anxiety demonstrate comorbidity 
with addiction and addicts cite stress as the number one reason for relapse to drug 
seeking.  Therefore, I attempt to integrate these conditions illustrating similarities in 
neurocircuits between addiction and stress/anxiety by characterizing a region that is 
uniquely positioned as a converging point, the bed nucleus of the stria terminalis (BNST).  
Finally I review metabotropic glutamate receptor (mGluR) function with an emphasis on 
integrating mGluR-mediated synaptic plasticity and neuradaptations in addiction and 
stress pathways.  In addition to illuminating basic mechanisms shared between addiction, 
stress and synaptic plasticity, work in these areas has important implications for human 
health.    
Addiction 
Addiction is a compulsive habit maintained despite harmful consequences 
(Nestler, 2001).  Drug addiction is the leading cause of lung cancer, and cirrhosis of the 
liver and costs society hundreds of billions of dollars due to loss of life and productivity 
(Vocci et al., 2005).  It is a complex disease involving many types of social and 
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psychological factors.  However, fundamentally it is a biological process: the effect of a 
chemical (drug of abuse) on a biological substrate (a brain).  Consequently, advances in 
the drug addiction field could potentially apply to other neurophysiological disorders 
such as stress/anxiety and depression, as well as to the basic mechanisms involved in 
learning and memory.  It is therefore a goal of this laboratory and many other research 
laboratories to study the physiological and molecular basis of drug addiction.  Ultimately, 
these studies are designed to gain a better understanding of neurobiology and may lead to 
development of pharmaceutical tools to intervene in neuropathological conditions such as 
the process of addiction.  
 
Addiction and Neuroplasticity 
There is an abundant literature on neurobiological changes associated with 
chronic drug exposure.  Therefore this document is focused on characterizing potential 
molecular substrates common to neuroadaptations mainly induced by a specific class of 
addictive drugs, psychostimulants.  Traditionally, the focus of scientific research on drug 
addiction has focused on alterations in dopamine (DA) signaling.  More recently, 
excitatory (glutamatergic) transmission has been recognized as a substrate for the 
neuroadaptations subsequent to drug intake.  In support of this, imaging studies of human 
addicts have shown that stimuli associated with drug use (e.g., drug paraphernalia) trigger 
drug craving while simultaneously activating glutamatergic circuits (reviewed in (Wolf, 
2002).   
The concept of drug-induced neuroplasticity was first proposed based on studies 
demonstrating that glutamatergic transmission, the key component for producing and 
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maintaining synaptic plasticity, is required for the development of behavioral 
sensitization—a prominent animal model of addiction discussed in a later section (Wolf 
and Khansa, 1991; Vanderschuren and Kalivas, 2000).  Moreover, it has been suggested 
that neuroadaptations leading to addiction involve the same glutamate-dependent cellular 
mechanisms that enable learning and memory (for reviews see (Berke and Hyman, 2000; 
Hyman and Malenka, 2001; Winder et al., 2002).  Long-term potentiation (LTP) as well 
as the counter effect, long term depression (LTD), are important characteristics of 
glutamatergic synaptic plasticity.  Phosphorylation states of key proteins, alterations in 
the availability of glutamate receptors at the synapse, and regulation of gene expression 
are thought to underlie LTP and LTD (Malinow and Malenka, 2002).  Abnormal 
recruitment of LTP or LTD in networks related to reward may be the first step in the 
cascade leading to the changes that underlie neuroadaptations elicited by substances of 
abuse.  Indeed, recent studies have begun to provide support for this hypothesis, showing 
that drugs of abuse can modify or induce LTP and LTD in neuronal pathways related to 
addiction (for review see Winder et al., 2002). 
 
Drugs of Abuse 
Drugs of abuse elicit their effects through different neurological mechanisms yet 
almost all of them recruit the natural reward pathways of the CNS, the mesocorticolimbic 
DA system.  Drugs of abuse fall into three categories: depressants (e.g. heroin, 
barbiturates), stimulants (e.g. cocaine, crack, amphetamines) and hallucinogens (e.g. 
marijuana, Ecstasy, LSD).  The research presented here will focus on stimulants. 
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Psychostimulants 
Psychostimulants, as the name suggests, are agents that activate or increase motor 
activity. The stimulants of high abuse potential, cocaine and amphetamines, interact with 
monoamine transporters (Amara and Sonders, 1998).  These transporters act to clear the 
monoamines from the extracellular space, particularly at the synapse, and therefore 
terminate the monoamine signal.  Cocaine blocks the monoamine transporters (dopamine 
transporter (DAT), norepinephrine transporter (NET) and the serotonin transporter 
(SERT)) thereby increasing the signaling properties of these systems.  Amphetamines 
also increase monoamine signaling but by a different mechanism.  Amphetamine and its 
derivatives act to reverse the monoamine transporter, thus increasing levels of 
extracellular monoamines and ultimately enhancing monoamine signaling (Koob, 1999).  
A defining characteristic of psychostimulants is their positive reinforcing effects.  
Positive reinforcement lends to enhanced drug seeking behaviors that can be readily 
studied as described in a subsequent section. 
 
Stages of Addiction 
Researchers have classified the characteristics of drug addiction into different 
stages.  It is important to note it is not necessarily easy to distinguish the behavioral 
indices characteristic of the stages of addiction.   From the behavioral perspective I will 
describe the stages of addiction as: initiation, dependence (tolerance and sensitization), 
withdrawal, maintenance, and relapse/reinstatement.  However, from the physiological 
perspective, I will discuss the charactersistics of drug addiction in two overlapping 
categories, the positive reinforcing aspects of drug intake which are thought to be largely 
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dopamine (DA) dependent and the withdrawal/relapse states which are hypothesized to 
be largely dependent on glutamatergic transmission. 
Initiation, as the term implies is the initial "recreational" use of a drug.  Tolerance 
is defined as the reduced drug responsiveness from repeated exposure to drug.  It is 
hypothesized that tolerance may contribute to the escalation of drug intake seen during 
the development of addiction. Dependence is an altered physiological (functional) state 
that develops to compensate for persistent drug exposure.  If a dependent individual 
ceases drug intake withdrawal may occur.  Withdrawal then may contribute to dysphoria 
(negative or aversive emotional state).  The physiological stress and state of dysphoria is 
thought to be a contributor to relapse to drug seeking.   
 
Maintenance of Addiction in the Absence of Continued Use   
Just as tolerance has been offered as an explanation of escalating drug seeking 
(Koob, 1996), the opposite phenomena,  sensitization, or enhanced drug responsiveness 
with repeated exposure to a constant dose, may contribute to the increased risk of relapse 
(Robinson and Berridge, 2000).  Much interest lies in sensitization due to its long-lasting 
effects characteristic of behavioral plasticity (Shippenberg et al., 2001).  Of greatest 
interest in addiction is the high risk of relapse.  Propensity to relapse persists even in 
abstinent addicts long after any withdrawal symptoms have subsided and perhaps for a 
lifetime (Weiss, 2005).  Relapse is driven by drug craving, an affective state that is hard 
to map onto a rodent.  However, models for studying relapse or reinstatement of drug 
seeking behavior have been developed and will be discussed in a subsequent section. 
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Reinstatement 
Reinstatement to drug seeking behavior can be induced by several mechanisms 
including re-exposure to the drug itself, drug-related cues and context or stress.  Briefly, 
exposure to the drug, or different drugs (cross-sensitization), can reinstate drug-seeking 
behavior in animals in which responding had been extinguished due to removal of the 
reinforcer (Shaham et al., 2003).   Glutamate release within the NAc increases during 
drug seeking behavior, and infusion of glutamate antagonist into this region blocks 
cocaine priming-induced reinstatement of drug-seeking behavior (Cornish and Kalivas, 
2000).  This suggests that glutamatergic transmission in the NAc is critical for drug-
induced reinstatement. 
Presentation of drug associated cues can elicit reinstatement of drug seeking in 
animals that have extinguished responding (Alleweireldt et al., 2001).  Interestingly, 
excitotoxic lesioning of the basolateral amygdala (BLA) has no effect on maintenance of 
cocaine administration but, attenuates cue-induced reinstatement to cocaine seeking (Meil 
and See, 1997).  Additionally, data suggests that a D1-like dopamine receptor (DAR) in 
the BLA is involved in cue-induced cocaine reinstatement (See et al., 2001). These 
findings suggest dopamine signaling in the BLA plays a critical role in cue-induced 
relapse to drug seeking. 
While re-exposure to a drug of abuse and drug associated cues can trigger relapse 
to drug seeking, addicts cite stress as the most powerful instigator of relapse to drug 
seeking (Koob, 1999; Sinha et al., 1999; Stewart, 2000).  The phenomena of stress-
induced increases in susceptibility to drug-seeking is observed in animal models as well 
(Erb et al., 1998; Lu et al., 2003).  Regions of the extended amygdala have been heavily 
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implicated in this aspect of relapse (Koob, 1999).  For instance, work from the Stewart 
lab implicates noradrenergic as well as CRF signaling in the BNST and CeA in stress-
induced reinstatement but not drug-induced reinstatment (Erb et al., 1998; Erb and 
Stewart, 1999; Erb et al., 2000; Shaham et al., 2000; Erb et al., 2001; Leri et al., 2002). 
  
Animal Models for Studying Effects of Drugs of Abuse 
One can study the influence of environmental factors, such as stress or 
pharmaceutical manipulations, on drug seeking behavior.  Outlined below are the two 
most commonly used procedures assessing rewarding effects of drugs in experimental 
animals:  intravenous drug self-administration and conditioned place preference (CPP).  
Additionally, behavioral sensitization, along with self-administration and CPP, is a 
method that is often used to assess relapse.   
The basic concept of self-administration relies on the ability of natural rewards, 
such as food and water, and drugs of abuse to act as positive reinforcers.   Animals press 
a lever which consequently leads to the infusion of the drug (i.e. cocaine).  This can in 
turn lead to positive reinforcement of the lever-pressing behavior (reviewed in Le Foll 
and Golberg, 2005, Schramm-Sapyta, 2005).  Stages of addiction (such as tolerance, 
desensitization) can be observed by this method. 
CPP is another commonly used behavioral task that is correlated to drug addiction 
mostly because of its technical simplicity.  More specifically, CPP is a model of drug 
reward among other things (Carr et al., 1988).  Briefly, an animal is trained to associate 
one side of a chamber with sensations felt after injection of a drug and the other with a 
neutral stimulus, such as a saline injection.  After repeated associative training, the 
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animal is allowed free choice between two sides of the chamber.  The time spent on the 
drug associated side of the chamber indicates the rewarding properties of the drug.  The 
task is more suitable to study early stages of drug addiction in which the drug is 
“enjoyable” (Schramm-Sapyta, 2005) yet can still be used as a model of relapse.  
Reinstatement of CPP in extinguished animals can be induced by drug priming (Mueller 
and Stewart, 2000) as well as stress (Wang et al., 2001; Lu et al., 2003).  
The development of enhanced behavioral sensitivity to psychostimulants with 
repeated administration has been well documented (reviewed in(Kalivas et al., 1998).  
Behavioral sensitization is typically characterized by an augmented motor responsiveness 
to a cocaine or amphetamine challenge.   The long-lasting changes mediating behavioral 
sensitization are suggested to in part underlie an increased susceptibility to relapse to 
drug seeking behaviors (Piazza et al., 1989; Robinson and Berridge, 1993).   
 
Anatomy of Addiction 
 
Brain Circuitry Involved in Reward 
Over two decades ago Olds and colleagues demonstrated that rodents will work to 
electrically stimulate relatively discrete areas of the brain, which demonstrates the 
existence of so-called, brain-reward regions (Olds, 1982; Wise, 1996). Subsequently, 
other groups found that rodents also work to self-administer drugs of abuse (but not other 
drugs) and that this self-administration behavior is disrupted by lesioning these brain-
reward regions (Koob, 1998; Wise, 1998).  The critical regions in the reward circuitry are 
now taken for granted as involving the mesolimbic dopamine system, more specifically 
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the VTA/NAc pathways (Figure 1)(Nestler, 2004).  Yet, the VTA-NAc pathways are 
only part of a series of parallel, integrated circuits, which involve several other key brain 
regions.  
 The VTA contains dopaminergic neurons, which are thought to convey 
information involved in integration of the rewarding vs. aversive properties of 
environmental stimuli (natural reward, drug of abuse, stress (Li et al., 2000)).  As 
suggested above, the VTA projects to the NAc and prefrontal cortex (PFC), which 
together are referred to as the mesocorticolimbic dopamine system.  Glutamate from 
various inputs such as the BLA, hippocampus,  PFC and even the BNST act on 
dopaminergic neurons in the VTA (Christie et al., 1985; Kim and Vezina, 1999; Georges 
and Aston-Jones, 2002). Therefore, glutamatergic output from these regions onto the 
VTA neurons are likely important in behaviors associated with addiction.   
The NAc, also known as the ventral striatum, is a principle target of VTA 
dopamine neurons and it mediates the rewarding effects of natural rewards and drugs of 
abuse (Koob, 1999). This region can be divided into at least two main subregions, the 
core and the shell.  Similar to the dorsal striatum, the NAc primary output neurons are 
GABAergic medium spiny neurons.  Neuronal activity in the NAc depends heavily on 
excitatory inputs from the PFC, hippocampus and the BLA.  Key to the rewarding effects 
of psychostimulants and other drugs of abuse is the role of dopamine signaling in the  
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Figure 1.  Schematic of reward pathways. 
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NAc.  For instance, cocaine is self-administered directly into the rat NAc (McKinzie et 
al., 1999; Rodd-Henricks et al., 2002), and injection of amphetamine into the NAc can 
induce reinstatement (Stewart and Vezina, 1988). 
The PFC is a critical part of the motivational network, it regulates the overall 
motivational significance and determines the intensity of behavioral responding 
(Goldstein and Volkow, 2002; Volkow et al., 2002).  In other words, cognitive processes 
involved in goal-directed behaviors are thought to depend on prefrontal cortex function 
(Hyman, 2005).  The output of the PFC is glutamatergic, and is modulated by DA among 
other neurotransmitters (Van Eden and Buijs, 2000).  Consistent with involvement of 
dopaminergic afferents, the activation of the prefrontal cortex by rewarding stimuli is 
strongly influenced by the predictability of the reward.  
The amygdala, more specifically the BLA, is particularly important for 
conditioned forms of learning. It is widely accepted that the amygdala is associated with 
fear conditioning and the processing of negative emotions. But this structure is also 
involved in the processing of positive emotions, and particularly in learning about the 
positive value of stimuli. It also interacts with the VTA-NAc pathway through excitatory 
inputs to these regions.  The BLA therefore acts to integrate the positive or negative value 
of an environmental stimulus (natural reward, drug of abuse, stress). 
The extended amygdala is connected with the VTA and several other brain 
structures hypothesized to be involved in the reinforcing effects of abused drugs (Koob, 
1999, 2003).  The extended amygdala is composed of several basal forebrain regions that 
have similar morphology, immunoreactivity and connectivity.  Along with the NAc shell, 
the BNST and the central nucleus of the amygdala (CeA) make up the extended 
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amygdala.  The extended amygdala is the aforementioned area implicated as a key 
mediator of stress-induced relapse (Stewart, 2000, 2003). 
 
Molecular Targets in Drug Addiction 
 
Dopamine and Drug Addiction 
Much research in the NAc has illuminated an intracellular signaling cascade 
downstream of DA which ultimately leads to changes in gene expression through which 
exposure to cocaine modifies subsequent responsiveness to the drug.  Dopamine 
transmission is upregulated during maintenance of the reinforcing properties of cocaine.  
Depletion of dopamine in the NAc decreases reinforcement behaviors (Roberts et al., 
1980; Pettit et al., 1984; Caine and Koob, 1994). Consistent with a role of increased DA 
in the NAc, D1-like and D2-like DA receptors are implicated in drug addiction.  The D1-
like DA receptors consists of D1 and D5 which are positively coupled to the cAMP 
signaling cascade, whereas D2-like receptors consist of D2, D3 and D4 and are linked to 
inhibition of adenylyl cyclase activity.  Antagonists of these receptors decrease the 
reinforcing effects of cocaine (Caine and Koob, 1994) for review see (Everitt and Wolf, 
2002).  More specifically D1-like and D2 DA receptor activation in the NAc reduces the 
reinforcing effects of cocaine (Caine et al., 1995; Bari and Pierce, 2005).  Furthermore, 
downstream mechanisms of DA receptor signaling have also been implicated in the 
reinforcing effects of cocaine and amphetamines.  For instance, chronic cocaine use 
resulted in decreased levels of the G-protein linked to inhibition of adenylyl cyclase 
activity, Gαi, which coincided with an increase in adenylyl cyclase and PKA activity 
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(Striplin and Kalivas, 1993; Schoffelmeer et al., 1996; Unterwald et al., 1996).  
Consistent with the effects of increased PKA activity following chronic cocaine use, it 
was found that injection of the nonhydrolyzable cAMP analogue Sp-cAMPS into the 
NAC increased cocaine self-administration (Self et al., 1998).  Another target 
downstream of D1-like DA receptors is the extracellular signal regulated kinase pathway.  
Recent discoveries show D1-like DA receptor dependent enhancement of ERK activation 
in a number of brain regions including the BNST following exposure to addictive but not 
non-addictive drugs (Valjent et al., 2004).   
Cocaine has been shown to alter gene expression downstream of DA receptor and 
cAMP signaling in the NAc (Nestler, 2004).  For instance overexpression of CREB in 
this region decreases the rewarding effects of cocaine, while reducing CREB signaling by 
overexpression of a dominant-negative mutant CREB increases the rewarding effects of 
cocaine (Carlezon et al., 1998). A potential downstream effect of DA receptor and cAMP 
signaling cascades in the NAc following cocaine or amphetamine exposure is alterations 
in synapse structure.  For instance, it was found that chronic amphetamine administration 
causes an increase in dendritic spine density and number of branched spines in the NAc 
(Robinson and Kolb, 1997).   
 
Glutamatergic Transmission and Drug Addiction 
A common feature of the brain regions of the reward circuitry studied to date (i.e. 
the NAc, VTA, BLA, and PFC) is that they possess high levels of glutamate receptors 
and are subject to multiple forms of synaptic plasticity.  It is therefore not surprising that 
drugs of abuse alter glutamatergic activity in these complex networks which leads to 
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fundamental changes in the output of the reward circuitry and ultimately the behavior of 
the organism.  Changes in glutamatergic transmission following exposure to drugs of 
abuse will be discussed in greater detail in later sections. 
 
Stress and Anxiety 
 As is the case for addiction, stress-related disorders such as anxiety and 
depression are a major health concern (Wong and Licinio, 2004).  Stress is the imposition 
or perception of environmental or physical change, either positive or negative, that elicits 
a spectrum of physiological homeostatic alterations in the organism (Herman and 
Cullinan, 1997).  Anxiety can be defined as a state of apprehension, uncertainty, and fear 
resulting from the anticipation of a realistic or imagined threatening event or situation.  In 
general, anxiety- and stress-related illnesses are thought of as a collection of disorders 
that have in common excessive or inappropriate brain excitability within crucial brain 
circuits, which leads to the expression of a spectrum of psychic (for example, excessive 
worry) or somatic (for example, disruptions of sleep, cardiovascular and gastrointestinal 
functions) symptoms. Anxiety disorders represent a range of conditions that include 
generalized anxiety, panic attacks, post-traumatic stress disorder, obsessive–compulsive 
syndrome and social phobias. 
 Adaptations to stressors result in complex responses involving changes in mood, 
cognition, behavior, autonomic function and endocrine output (Dayas et al., 2001). A key 
component in the neurocircuitry of stress is the hypothalamo-pituitary-adrenocortical axis 
(HPA).  The hypothalamus is the major integrating link between the nervous system and 
the endocrine systems.  Briefly, painful, stressful, and emotional stimuli can lead to 
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activation of the paraventricular nucleus of the hypothalamus (PVN).  Hormones released 
from the hypothalamus in turn stimulate or suppress the pituitary gland by secretion of 
releasing hormones or inhibiting hormones, respectively.  The pituitary is then capable of 
secreting corticotrophs which leads to secretion of adrenocorticotrophic hormone 
(ACTH) which then can stimulate the adrenal cortex to secrete glucocorticoids.    
 Ultimately, the secretion of corticotrophin-releasing hormone, a key neuropeptide 
involved in integrating hormonal, autonomic and behavioral responses to stress is a 
critical mediator of the anxiety state (Koob, 1999).  However, much work has 
demonetrated that dopamine is one of the transmitters most potently modulating the 
mechanisms underlying states of fear and anxiety (Millan, 2003). The limbic system has 
been linked to emotionality, emotional evaluation of sensory stimuli, emotional learning 
and memory, and affective disorders (anxiety and depression).  Additional components in 
the stress response are the afferent regions that modulate the HPA axis including parts of 
the limbic system, cerebral cortex and thalamus (Figure2).    
In addition to the neurotransmitters traditionally known to be involved in 
stress/anxiety disorders, the monoamines,γ-amino-butyric acid (GABA), and many other 
modulators have been targeted for therapeutic intervention of stress/anxiety disorders.  
These include but are not limited to adenosine, cannabinoids, neuropeptides, hormones 
and glutamate. Accordingly, though benzodiazepines (which reinforce transmission at 
GABAA receptors), serotonin (5-HT)1A receptor agonists and 5-HT reuptake inhibitors 
are currently the main drugs used for treatment of anxiety disorders, there is considerable 
scope for the development of alternatives (Millan, 2003).  However, targeting these 
systems has proven to have either limited efficacy or unwanted side effects.  For instance, 
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dysregulation of monoaminergic function cannot fully explain psychiatric disorders.  The 
modulation of glutamatergic transmission by mGluRs has promising therapeutic 
implications for treating stress/anxiety disorders and will be the focus of later sections.   
 
Processive vs. Systemic stress 
Stressors can be separated into at least two categories “processive” and 
“systemic” (Herman and Cullinan, 1997).  Processive stressors recruit brain regions 
involved in higher order decision making to determine if a perceived stimulus is 
“stressful”.  Systemic stressors are innate responses to a stimulus that poses a direct 
immediate threat to survival such as a hemorrhage or hypoxia.  Systemic stressors do not 
require higher level processing to elicit a response (Herman and Cullinan, 1997).   
A key anatomical and functional converging point of the processive and systemic stress 
pathways prior to reaching the PVN is the BNST.  As the BNST is composed of multiple 
subnuclei, the effects of activation of this region by specific stimuli are complex.  For 
instance, electrical stimulation of the lateral BNST resulted in a decrease in plasma 
corticosterone levels, an output of the HPA axis, while stimulation of the medial BNST 
had the opposite effect (Dunn, 1987).  Additionally, lesioning the anterolateral BNST 
results in a decrease in CRF mRNA in the PVN whereas lesioning the posterior medial 
BNST results in an increase in CRF mRNA in the PVN (Herman et al., 1994). 
 
Bed Nucleus of the Stria Terminalis (BNST) 
The BNST is a key anatomical bridge uniquely positioned to integrate responses 
to stress as well as drugs of abuse (Figure 3). It is located along a rostral-caudal gradient  
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Figure 2.  Schematic of stress circuitry. 
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in the rostral portion of the basal forebrain.  The BNST consists of many nuclei which 
have been grouped into divisions.  Original data presented in this thesis were obtained 
from neurons in the anterior division of the BNST which can be divided into the 
anterodorsal, anterolateral and anteroventral areas (which will sometimes be referred to 
as the dorsolateral BNST or dBNST).  More specifically, the dBNST can be divided into 
separate nuclei;  the antolateral nuclei, consisting of the juxtacapsular, oval rhomboid, 
and fusiform nuclei (Dong et al., 2001).  Physiologically, the BNST has multiple 
functions which include but are not limited to the integration of information to the stress 
and reward pathways.  A majority of BNST neurons stain positive for glutamic acid 
decarboxylase (GAD), the enzyme responsible for the conversion of glutamate to GABA 
(Sun and Cassell, 1993).  This would suggest the primary output of the BNST is 
GABAergic; however, evidence for other neuropeptides and glutamatergic outputs exist 
(Ju and Swanson, 1989; Georges and Aston-Jones, 2002). 
 Characterization of membrane properties of BNST neurons was done by the 
Winder lab as well as preliminary work reported by Donald Rainnie (Rainnie, 1999; Egli 
and Winder, 2003).  Briefly, neurons in the BNST have a resting membrane potential of -
68 to -69 mV and a reported input resistance of approximately 115-128 MΩ when 
measured with sharp microelectrodes (Egli and Winder, 2003).  An important feature of 
these neurons is that they are under tonic GABAergic inhibition, possibly keeping these 
cells in a quiescent state.   
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Figure 4. Diagram illustrating the extended amygdala, its neuropharmacological 
components, afferent and efferent connections and functional attributes (Adapted from 
Koob, 2004). 
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BNST Afferents 
 The BNST receives excitatory inputs primarily from the ventral subiculum of the 
hippocampus, limbic cortical regions and BLA inputs (Cullinan et al., 1993; Snyder et al., 
2001).  The glutamatergic inputs to the BNST are variable.  For instance, infralimbic 
cortical inputs are lighter to the dBNST in respect to the vBNST.  Additionally, there are 
are no direct inputs from the prelimbic cortex to the dBNST with only light innervation to 
the vBNST (McDonald et al., 1999).   
There is also functional and behavioral evidence suggesting glutamatergic inputs 
to the BNST are important in the output of this region.  Of behavioral relevance, 
blockade of non-NMDA ionotropic glutamate receptors (iGluRs) transmission in the 
BNST resulted in an attenuation of fear-potentiated startle (Walker and Davis, 1997).  
Functionally, Boudaba and colleagues were able to elicit IPSPs in the PVN in response to 
glutamate puffing in the posterior BNST (Boudaba et al., 1996).  Additionally, recent 
work in the Winder lab has shown local stimulation of the BNST in an in vitro slice 
preparation elicits excitatory AMPA receptor mediated currents that are sensitive to 
noradrenergic modulation (Egli and Winder, 2003; Egli et al., 2005).   Further work from 
the Winder lab demonstrated that NMDAR-dependent LTP of excitatory transmission 
can be elicited in this region and that this LTP is sensitive to ethanol (Weitlauf et al., 
2004).      
In addition to glutamate, the BNST also receives noradrenergic, dopaminergic, 
serotonergic and CRF inputs.  NE inputs arise primarily from the ventral noradrenergic 
bundle (Roder and Ciriello, 1994).  Consistent with NE innervation of the BNST, NE can 
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modulate the activity of BNST neurons as well as synaptic transmission (Egli and 
Winder, 2003; Egli et al., 2005).   
There is a strong dopaminergic input to the dorsal BNST coming from various 
brain regions including the substantia nigra, VTA, dorsal raphe nucleus, periaqueductal 
gray and the brain stem through the medial forebrain bundle (Sawada and Yamamoto, 
1981; Phelix et al., 1992; Hasue and Shammah-Lagnado, 2002).  Consistent with other 
brain regions which receive a vast dopaminergic innervation, drugs of abuse such as 
nicotine, morphine, cocaine, amphetamine, and ethanol increase dialysate DA levels in 
the BNST. It is notable that the magnitude of the effect and the sensitivity to the drug is 
higher in this area as compared to the NAc shell (Di Chiara et al., 1999).  
Serotonergic input to the BNST is from the midbrain raphe nuclei (Phelix et al., 
1992, 1992).  Functional studies have shown that c-fos expression in the BNST is 
increased by in vivo manipulations that either enhance, or deplete, 5-HT levels (Li and 
Rowland, 1996; Chung et al., 1999; Morelli and Pinna, 1999). Additionally activation of 
serotonergic system in the BNST, most likely through 5-HT1A, leads to an inhibition of 
BNST neurons (Rainnie, 1999; Levita et al., 2004). 
 
BNST Efferents 
As has been suggested by the arguments above, the BNST acts as a key 
intermediary by receiving stressor inputs from cortical regions and sending its own 
projections to the stress response regions of the brain, more specifically the PVN, to 
regulate hormonal CRF release and pituitary activation and ultimately the stress response.  
Several regions are reciprocally connected to the BNST. For instance, the BNST sends 
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projections to the VTA, raphe nucleus and the CeA, all of which send projections back to 
the BNST.  Of great importance, the BNST is one of a discrete set of regions innervating 
the parvocellular CRF-containing PVN neurons including the other hypothalamic 
subnuclei, brainstem nuclei such as the raphe and the nucleus of the solitary tract 
(Marsicano et al., 2003).   
Consistent with interconnectivity to the stress pathways, inhibition of 
glutamatergic transmission in the BNST by AMPA receptor antagonists blocks stress 
responses to some stressors.  Specifically, glutamatergic inhibition in the BNST leads to 
blockade of light enhanced startle and CRH-mediated startle, but not fear-potentiated 
startle (Walker et al., 2003).   Therefore, excitatory, glutamatergic transmission in the 
BNST plays a critical role in the response to stress and anxiety.   
In addition to the BNST being interconnected to the stress axis, it is a brain region 
uniquely positioned to regulate reward centers.  For example, the dBNST sends 
projections to the NAc (Dong et al., 2001).  Furthermore, as mentioned above, the 
vBNST projects to and regulates the firing of dopaminergic cells within the VTA 
(Georges and Aston-Jones, 2002). There is evidence from microinfusion of ionotropic 
glutamate receptor antagonists indicating glutamatergic influence on VTA cells from 
efferents of the vBNST (Georges and Aston-Jones, 2002).  Thus the BNST is uniquely 
positioned to receive stress axis information and integrate it into reward/motivation 
circuitry.  
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The BNST and Stress-Induced Relapse to Drug Seeking 
Consistent with the anatomical interconnections mentioned above, recent data 
demonstrate that the BNST plays a key role in mediating stress-induced relapse to 
cocaine-seeking behavior (Erb and Stewart, 1999; Sinha et al., 1999; Shaham et al., 2000; 
Erb et al., 2001), as well as in stress-induced maintenance and reinstatement of morphine-
conditioned place preference (Wang et al., 2001).  Furthermore, Delfs et al. (2000) 
showed that the BNST plays a key role in morphine withdrawal–induced conditioned 
place aversion (Delfs et al., 2000).  Additional work in the vBNST suggested that 
excitatory synaptic transmission is enhanced following cocaine self-administration 
(Dumont et al., 2005).  The background present here makes synaptic plasticity in the 
BNST an attractive substrate for mediating drug-related behaviors. 
 
Synaptic Transmission 
Cells of the central nervous system consist of neurons and glia.  Most information 
transfer in the brain is via an electrical and chemical process referred to as synaptic 
transmission (Kandel et al., 2000).  Neurons exhibit specific organization of their 
membrane components that allow for electrical signaling.  A typical neuronal response 
involves the depolarization of a cell body that leads to the propagation of an electrical 
signal down the axon.  At the end of the axon are specialized structures called presynaptic 
terminals.  Depolarization of the presynaptic terminals results in calcium entry and 
transiently enhances the probability of release of neurotransmitter from synaptic 
terminals.  Neurotransmitters, the chemical component of the electro-chemical signal, act 
at receptors on postsynaptic membranes.  Dendrites are the specialized region of neurons 
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and are the primary target for synaptic input.  As such they act to receive and integrate 
information from other neurons. The postsynaptic membrane contains ligand-gated ion 
channels that, when activated flux sodium and potassium (sometimes calcium) which 
results in the depolarization of the local membrane.  If the membrane is sufficiently 
depolarized, an action potential is propagated down the dendrites to the cell body and 
thus the process can repeat down the axon to the next synapse in the circuit.  Synaptic 
transmission can be grouped into three forms: fast excitatory, fast inhibitory and 
neuromodulatory.  The focus of this thesis is on excitatory transmission and its 
modulation. 
 
Excitatory Transmission
Glutamate is the major excitatory neurotransmitter in the mammalian brain.  Since 
its discovery as a neurotransmitter in 1954 (Hayashi, 1954), glutamate has been 
investigated for its function in various processes including but not limited to neuronal 
plasticity and more recently neuromodulation.  Due to the immense literature, the aim of 
this introduction on glutamatergic transmission is to provide an overview of excitatory 
transmission and neuromodulation of synaptic transmission by mGluRs.  An emphasis is 
placed on how synaptic plasticity, mGluRs and their potential downstream targets play a 
role in drug addiction and stress/anxiety.   
Different classes of glutamate receptors in the postsynaptic membrane transduce 
the glutamate signal released from the presynaptic terminal into electrical and 
biochemical events in the postsynaptic neuron. Glutamate release from synapses activates 
ion channel-forming receptors, the iGluRs, at postsynaptic cells and consequently 
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mediates fast excitatory postsynaptic transmission.  The subsequent discovery of 
metabotropic glutamate receptors (mGluRs) revealed that glutamate can also mediate 
slow synaptic potentials, modulate ion channels and activate GTP binding proteins.  
MGluRs will be discussed in detail later. 
The iGluRs are classified as NMDA (NR1, NR2A D, NR3), AMPA (GluR1 4) 
and kainate (GluR5 7, KA1 2) receptors, based on their pharmacological characteristics 
and sequence information (Hollmann and Heinemann, 1994; Borges and Dingledine, 
1998; Dingledine et al., 1999). Whereas AMPA and kainate receptors contribute to fast 
neurotransmission, all three ionotropic subtypes are thought to play roles in synaptic 
plasticity (Bortolotto et al., 1999).  AMPA receptors (AMPARs) are hetero-oligomeric 
proteins that form a tetrameric receptor complex (Rosenmund et al., 1998). In the adult 
hippocampus two species of AMPAR appear to predominate: receptors made of GluR1 
and GluR2 or those composed of GluR3 and GluR2 (Wenthold et al., 1996).  The 
AMPAR complexes from ligand-gated ion channels that when bound by glutamate, flux 
sodium and potassium (sometimes calcium) consequently depolarizing the cell 
membrane.  The resulting effect can be recorded as a potential (excitatory postsynaptic 
potential, EPSP) or a current (excitatory postsynaptic current).  The NMDA receptor is an 
ion channel that is inactive at resting membrane potentials due to a voltage sensitive 
magnesium block.  Upon ligand binding (glutamate and glycine) and a sufficient 
depolarization, NMDA receptors flux sodium, potassium and calcium.  Regulation of 
AMPA receptors will be covered in more detail in a later section. 
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Synaptic plasticity 
Bliss and Lomo (1973) obtained the first solid experimental evidence supporting 
the theory that information storage in the brain involves alteration in the strength of 
synaptic communication between mammalian neurons.  A lasting alteration in synaptic 
strength is referred to as synaptic plasticity.  Synaptic plasticity lasts for many hours in 
brain slices and even for weeks in intact animals (Bliss and Gardner-Medwin, 1973; Bliss 
and Lomo, 1973; Malenka and Nicoll, 1999).  In long term potentiation (LTP), brief 
repetitive stimulation of excitatory glutamate containing pathways (produced by high 
frequency stimulation, referred to as a tetanus) leads to an increase in synaptic strength.  
Different (usually lower frequency) patterns of synaptic activation produce an opposite 
change, termed long term depression (LTD) (Dudek and Bear, 1992; Mulkey and 
Malenka, 1992; Kirkwood et al., 1993).   
Changes in synaptic efficacy can occur by presynaptic mechanisms such as 
altered neurotransmitter release as well postsynaptic mechanisms.  One primary means of 
persistently modulating synaptic transmission is by changing the activity or abundance of 
postsynaptic AMPAR’s (Carroll et al., 1999).  A more detailed description of synaptic 
locus is developed in the mGluR section. 
 
AMPAR regulation 
The expression of excitatory synaptic plasticity is largely thought to be mediated 
by alterations in AMPA receptor expression and function in the postsynaptic cell.  
Additionally, changes in subunit composition can influence AMPA receptor function as 
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this composition influences the functional properties of iGluRs (Borges and Dingledine, 
1998; Dingledine et al., 1999).   
The regulation of AMPAR function during synaptic plasticity occurs via two 
related mechanisms.  First, there is evidence for covalent modification (phosphorylation 
and dephosphorylation) of synaptic AMPARs resulting in an enhanced ion flux.  For 
instance, CaMKII phosphorylation of GluR1 leads to an increase in single channel 
conductance of AMPARs (Derkach et al., 1999).  Changes in phosphorylation of GluR1 
at S831 (Esteban, 2003; Esteban et al., 2003), a CaMKII/PKC site and at S845 (Roche et 
al., 1996; Barria et al., 1997; Mammen et al., 1997), a PKA site also occur during LTP 
and LTD.  
Second, like all integral membrane proteins, glutamate receptors turn over in the 
membrane and importantly phosphorylation is implicated in this process as well. Activity 
can drive AMPARs into the synapse resulting in LTP (Liao et al., 2001; Esteban, 2003; 
Esteban et al., 2003) or remove them from the synapse resulting in LTD (Lissin et al., 
1999).  Along with lateral movement from extrasynaptic sites, increasing or decreasing 
AMPARs levels at the synapse occurs via vesicular exocytosis and endocytosis (Carroll 
et al., 1999).   
AMPARs are delivered to synapses through two different pathways, depending on 
their subunit composition.  As mentioned above, they contain tetrameric combinations of 
subunits GluR1 to GluR4 (Keinanen et al., 1990), each interacting with a specific set of 
intracellular proteins (Scannevin and Huganir, 2000). An important distinction among 
AMPAR subunits is the nature of their C-terminal tails, which are either long or short.  
GluR1 always has a long C-terminal tail and GluR4 a short C-terminal tail.  The C-
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terminal tails of GluR 2 and 3 are alternatively spliced such that these subunits can have 
either long or short C-terminal tails. 
Cycling of GluR1 (long form) to the postsynaptic membrane requires synaptic 
activity whereas GluR2 (short form) membrane expression is constitutively turning over 
(Passafaro et al., 2001; Piccini and Malinow, 2002).  There are also constitutive and 
regulated pathways for removal of AMPA receptors from the synapse as well (Carroll et 
al., 1999; Carroll et al., 2001; Luscher and Frerking, 2001; Bredt and Nicoll, 2003).  
Regulated endocytosis of postsynaptic AMPA receptors mediates many types of LTD, 
including NMDA receptor-dependent LTD, mGluR-dependent LTD, and 
endocannabinoid-dependent LTD (Malenka and Bear, 2004).  LTD appears to involve the 
internalization of GluR1 containing AMPA receptors as well as AMPA receptors that 
overlap with the constitutively recycling pool, GluR2 (Collingridge et al., 2004).  
Therefore, molecules involved in membrane trafficking and structural integrity of the 
postsynaptic signaling complexes play an important role in the initiation and maintenance 
of synaptic plasticity. 
 
Psychostimulants and Glutamatergic Synaptic Plasticity 
As mentioned earlier, although psychostimulants such as cocaine directly interact 
with monoaminergic signaling (e.g. DA, NE and 5-HT), there is a strong body of 
evidence suggesting alterations in excitatory synaptic plasticity play an important role in 
behaviors related to addiction (Thomas et al., 2001; Beurrier and Malenka, 2002; 
Fourgeaud et al., 2004).   
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As mentioned above, dopamine neurons in the VTA receive dense glutamatergic 
innervation (Christie et al., 1985; Kim and Vezina, 1999; Georges and Aston-Jones, 
2002), interestingly, these synapses have been shown to undergo synaptic plasticity 
subsequent to in vivo treatment with several drugs of abuse.  More specifically drugs of 
abuse elicit increased excitatory input (LTP as defined by increases in AMPA/NMDA 
ratios) while attenuating LTD mechanisms in the VTA (Jones et al., 2000; Ungless et al., 
2001; Saal et al., 2003; Borgland et al., 2004).  Further studies revealed that amphetamine 
blocks LTD in the VTA via release of DA and activation of D2 receptors.  Another 
potential mechanism for increased synaptic efficacy of VTA dopamine neurons is an 
increase in AMPA receptor expression following cocaine administration (Fitzgerald et 
al., 1996; Lu et al., 2002; Lu et al., 2004). Similarly, in humans, cocaine overdose is 
associated with VTA up-regulation of the GluR2 AMPA receptor subunit (Tang et al., 
2003). 
Downstream of the VTA, NMDAR-dependent LTD in the NAc in naïve animals 
is unaltered by DA or DA receptor antagonists (Thomas et al., 2000) and is associated 
with internalization of AMPA receptors and decreases in synaptic AMPA receptor 
expression (Heynen et al., 2000; Malinow and Malenka, 2002). However, to complicate 
matters, variances in molecular targets of drugs of abuse in the NAc during different 
stages of addiction have been observed.  For instance, in contrast to drug-induced 
regulation of synaptic plasticity in the NAc, extinction training during withdrawal from 
chronic cocaine self-administration leads to an up-regulation in both GluR1 and GluR2 
AMPA subunits in the NAc (Lu et al., 2003; Sutton et al., 2003), the same subregion 
exhibiting LTD in cocaine withdrawal (Thomas et al., 2001). Extinction training 
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diminishes cocaine-seeking behavior as animals learn that cocaine reinforcement is no 
longer available.  This leads to a strong correlation between AMPA receptor expression 
in the NAc and drug seeking behavior. Furthermore, either GluR1 or GluR2 over-
expression during extinction training leads to prolonged attenuation of stress-induced 
relapse to cocaine seeking (Self and Choi, 2004).  
 
Neuromodulation 
 Neuromodulation is a subtle influence on synaptic efficacy or neuronal 
excitability.  It is this “fine tuning” by neuromodulators that make them attractive 
therapeutic targets for disorders such as addiction and stress/anxiety.  Neuromodulation 
occurs through signaling of neurotransmitters, such as monoamines, glutamate or 
neuropeptides working primarily through G-protein coupled receptors.  Neuromodulation 
can also involve longer-lasting changes such as alterations in gene expression.  As 
mentioned above, and as the major focus of this thesis, there are mGluRs that function to 
modulate neuronal transmission.  Other neuromodulatory systems include metabotropic 
GABA receptors, monoamine neurotransmitter receptors and multiple neuropeptide 
systems such as CRF. 
 
G-Protein Coupled Receptors 
 G-protein coupled receptors (GPCRs) are 7 transmembrane domain proteins that 
interact with G-proteins.  Receptor activation leads to associated G-protein hydrolase 
activity and ultimately to activation or inhibition of an effector protein (Pierce et al., 
2002).  G-protein regulation of effectors occurs through two broad mechanisms.  First 
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there is direct G-protein binding to ion channels.  More traditionally, G-proteins function 
to activate or inhibit second messenger-forming enzymes leading to:  direct second 
messenger binding to ion channels, second messenger activation of kinases or 
phosphatases that phosphorylate/dephosphorylate ion channels, or alterations in protein-
protein interactions involving an ion channel. 
 There are multiple potential consequences of neuromodulation.  Neuromodulation 
can lead to changes in probability of neurotransmitter release, small depolarization of 
membrane potentials accompanied by small conductance changes, small 
hyperpolarization of membrane potential accompanied by a conductance that resists 
depolarization, closing of K+ channels that prevent neurons from reaching AP threshold 
(e.g. M-type K+ current inhibition) and alterations in repolarization of the action 
potential.  There are many channels that are potential targets of neuromodulation that lead 
to the aforementioned changes in membrane excitability.  For example:  voltage-gated 
channels (Na+, K+, Ca2+), inwardly rectifying K+ channels, channels that are active at 
RMP (i.e. “leak conductance” channels), ligand-gated channels (such as AMPARs) and 
cyclic nucleotide-gated channels.   
 
Metabotropic Glutamate Receptors 
In the mid-80’s, glutamate was shown to stimulate IP3 production indicating the 
potential existence of a “metabotropic” or non-ion-channel-forming glutamate receptor 
(reviewed in (Coutinho and Knopfel, 2002).  This led to the distinction between 
ionotropic and metabotropic glutamate receptors and the search for the receptors 
responsible for the IP3 production.  In 1991, two groups isolated and cloned cDNA of the 
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first mGluR (Houamed et al., 1991; Masu et al., 1991).  Today there are eight subclasses 
of mGluRs identified and cloned. MGluRs belong to family C of the G-protein 
coupled receptor superfamily and act to modulate neuronal excitability in many brain 
regions.  The subclasses are classified into three groups based on pharmacology, 
similarities in coupling mechanisms and sequence homology (Table 1).   MGluRs of the 
same group show about 70% sequence identity, whereas between groups this percentage 
decreases to about 45%.  Group I receptors (mGlu1 and mGlu5) are linked to Gαq, 
whereas, group II and group III mGluRs are coupled to Gαi (Gereau and Conn, 1994; 
Anwyl, 1999). Intracellularly, the large C-terminus of mGluRs can interact with a variety 
of signaling systems.   
 
Functions of MGluRs 
MGluRs largely extended the classical role of glutamate as a fast excitatory 
synaptic transmitter, acting as a neuromodulator and even as an activator of inhibitory 
mechanisms at certain synapses.  They are widely distributed throughout the CNS, where 
they play important roles in regulating cell excitability and synaptic transmission (Gereau 
and Conn, 1994). More specifically, they can activate enzymes such as kinases which 
result in modifications in physiological functions such as the modulation of synaptic 
transmission, synaptic integration, and plasticity. In addition to activation of intracellular 
signaling cascades, direct and indirect modulation of various voltage sensitive ion 
channels by mGluRs results in a faster action on neuronal physiology. This impact on 
physiological activity is of principal interest as the firing pattern of neuronal networks, 
and changes in synaptic plasticity in these networks as a consequence of a behavioral 
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experience may provide a basis for understanding the role of mGluRs in 
pathophysiological conditions such as stress/anxiety and addiction. 
 
Table 1.  Classification of mGluRs 
Family 
receptor 
Coupling Group/subtype-selective pharmacological 
agents 
Group I     
mGluR1 Gq-
coupled 
Agonists:  DHPG, 1S,3R-ACPD, quisqualate  
Antagonist:  LY393675                                       
Inverse agonist (allosteric antagonist):  LY367385 
mGluR5 Gq-
coupled 
agonists:  DHPG, 1S,3R-ACPD, quisqualate, CHPG    
Inverse agonist (allosteric antagonist):  MPEP 
Group II     
mGluR2 Gi/o-
coupled 
Agonists:  DCG-IV, LY354730, 1S,3R-ACPD           
Antagonist:  LY341495 
mGluR3 Gi/o-
coupled 
Agonists:  DCG-IV, LY354730, 1S,3R-ACPD           
Antagonist:  LY341495 
Group III     
mGluR4 Gi/o-
coupled 
Agonists:  L-AP4, L-SOP                               
Antagonist:  MSOP, MAP4 
mGluR6 Gi/o-
coupled 
Agonists:  L-AP4, L-SOP                               
Antagonist:  MSOP, MAP4 
mGluR7 Gi/o-
coupled 
Agonists:  L-AP4, L-SOP                               
Antagonist:  MSOP, MAP4 
mGluR8 Gi/o-
coupled 
Agonists:  L-AP4, L-SOP, 3,4-DCPG                            
Antagonist:  MSOP, MAP4 
Modified from Swanson et al., 2005. 
 
 
Glutamate Sources from which MGluRs can be Activated 
Overall mGluRs have beens shown to be primarily located perisynaptically.  That 
is, mGluRs are often located in the areas adjacent to the synapse (Baude et al., 1993; 
Lujan et al., 1997).  Functionally, their location suggests that they become activated in 
situations of repeated stimulation of afferents which results in considerable glutamate 
accumulation in the synaptic cleft coupled to spill-over to extra-synaptic sites.  Therefore, 
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in an attempt to increase the amount of glutamate released at the synapse and to mimic 
physiological glutamate release, low frequency stimulation (LFS) is a commonly 
incorporated method to activate mGluRs (Charpak and Gahwiler, 1991; Batchelor and 
Garthwaite, 1997). This indicates that detectable receptor activation in many cells 
requires pooling of glutamate in order to reach sufficiently high levels at the 
extrasynaptic mGluR sites (Baude et al., 1993; Nusser et al., 1994).  
In addition to the frequency of release, the extracellular concentration of 
glutamate also depends on the efficacy of neuronal and glial uptake, which is dictated by 
the number of glutamate transporters (for review see (Baker et al., 2002)). Glutamate 
transporters (GluTs) along with passive diffusion are the primary means of glutamate 
removal from the extracellular space.  They function to prevent the accumulation of 
glutamate and influence the occupancy of receptors at synapses. The ability of 
metabotropic glutamate receptors to participate in signaling is tightly regulated by GluT 
activity (Kawasaki et al., 2004).  
Another contributor to extrasynaptic glutamate is the cystine-glutamate 
exchanger.  The non-synaptic cystine—glutamate antiporter exchanges extracellular 
cystine for intracellular glutamate, with a minimal contribution of synaptic glutamate 
release (Baker et al., 2002). Data from Kalivas' group suggests that one form of cocaine-
induced neuroadaptation may be the decrease in basal levels of extracellular glutamate in 
the NAc after several weeks of withdrawal from cocaine, an effect attributed to a reduced 
function of the cystine—glutamate transporter (Baker et al., 2003; Moran et al., 2005).  
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Group I MGluRs   
Group I receptors (mGluR1 and mGluR5) are linked to activation of 
phospholipase C leading to phosphoinositide hydrolysis, calcium release and protein 
kinase C activation.  Activation of group I mGluRs can also indirectly regulate adenylyl 
cyclase leading to increased cyclic AMP formation, as well as cyclic GMP accumulation, 
PLA and ERK activation (Gereau and Conn, 1994; Anwyl, 1999).  
To date, no one has looked at the expression of group I mGluRs in the BNST; 
however, they have been shown to be expressed in other brain regions belonging to the 
stress axis as well as the reward circuitry.  Group I mGluR function has been reported at 
many of these synapses as well.  For instance, both mGluR1 and mGluR5 function in the 
NAc and the PFC.  However, although highly homologous, studies suggest these 
receptors have distinct functions in regulating synaptic transmission (Gereau and Conn, 
1994; Attucci et al., 2001).  This implies differential regulation of these receptors and 
potential divergence in effector systems. Conversely, at some synapses only one type of 
group I mGluR is functionally important: for instance only mGluR1 has been shown to 
function in the VTA and cerebellum (Shigemoto et al., 1992; Batchelor et al., 1997; 
Bellone and Luscher, 2005).   
Group I mGluR expression at the plasma membrane and its signaling properties 
are dependent upon scaffolding proteins, more specifically, Homer proteins.  There are 
three genes encoding Homer proteins.  Homer 1a is an immediate-early gene product 
while the remainder (Homer 1b/c, Homer 2 and Homer 3) are constitutively expressed 
(Brakeman et al., 1997).  Homer proteins link group I mGluRs through the C-terminal tail 
(Xiao et al., 2001).  They are part of the scaffolding at postsynaptic densities (PSD) and 
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therefore link group I mGluRs with the proteins in the PSD.  Homers also link these 
receptors to intracellular calcium stores via IP3 receptors and other scaffolding proteins 
such as Shank (Brakeman et al., 1997).  It is suggested that Homer proteins may regulate 
the expression and function of group I mGluRs at multiple levels including targeting, 
surface expression, clustering, physical linkage to other synaptic and subsynaptic 
complexes and modulation of constitutive activity.  Interestingly, biochemical evidence 
suggests the C-terminus of Homer 2a interacts with the Rho family of small guanosine 
triphosphatases (GTPases), in a GTP-dependent manner (Shiraishi et al., 1999).  Homer 
proteins have been also been shown to form complexes with Shank proteins which act as 
scaffolding proteins and link group I mGluRs with other proteins in the postsynaptic 
densities (PSD) such as Dynamin2, an important molecule indicated in endocytosis and 
AMPAR-glutamate receptor interacting protein (GRIP) complexes (Tu et al., 1999).   
 
Pharmacology of Group I MGluRs 
The recent development of mGluR selective ligands (e.g. phenylglycine 
derivatives acting either as agonists or as antagonists) has helped begin the elucidation of 
the functional roles of mGluRs in brain and behavior. The pharmacological profile of 
group I mGluRs has been determined in mammalian heterologous expression systems on 
cloned mGluRs (Gereau and Conn, 1994).  The rank order of potency of the most 
common agonists is: quisqualate>3,5-dihydroxyphenylglycine 
(DHPG)=glutamate>1S,3R-1-amino-1,3-cyclopentanedicarboxylate (ACPD) (Gereau and 
Conn, 1994; Pin and Duvoisin, 1995). The specific agonist for group I mGluRs used in 
the studies presented below is DHPG, which is devoid of activity at other mGluRs (Ito et 
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al., 1992; Fitzjohn et al., 1998). An agonist for mGluR5 has been reported (RS)-2-chloro-
5-hydroxyphenylglycine (CHPG), although it is not very potent (Doherty et al., 1997). 
The first antagonist described for group I mGluRs was α-methyl-4-
carboxyphenilglycine (MCPG).  However, MCPG also antagonizes group II mGluRs 
(reviewed in (Bordi and Ugolini, 1999).  There are several drugs that selectively inhibit 
mGluR5; the most widely used is the noncompetitive antagonist MPEP (2-methyl-6-
phenylethynyl-pyridine), with the caveat that at high concentrations it blocks NMDA 
receptors (Spooren et al., 2001). 
 
Synaptic Locus of Group I MGluRs 
  Mechanisms underlying group I mGluR function vary across brain regions and 
synapses.  Much information on function of these receptors can be gained by determining 
the synaptic locus of action of these receptors.  Immunohistochemical and 
electrophysiological results reveal group I mGluRs localize and function presynaptically, 
postsynaptically and on glia (Shigemoto et al., 1993; Romano et al., 1995; Balazs et al., 
1997; Conn and Pin, 1997; Lujan et al., 1997; Manzoni et al., 1997; Lopez-Bendito et al., 
2002). However, group I mGluRs are predominantly located at the periphery of the 
postsynaptic density (perisynaptically) (Baude et al., 1993; Lujan et al., 1997).  
Activation of group I mGluRs cause postsynaptic effects such as neuronal depolarization, 
excitation and spike frequency adaptation in a number of brain regions.  For instance, 
selective activation of group I mGluRs with DHPG increases postsynaptic membrane 
excitability in hippocampus (Muda et al., 1996), cortex (Libri et al., 1997; Attucci et al., 
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2001), striatum (Pisani et al., 1997), amygdala (Keele et al., 1997), subthalamic nucleus 
(Abbott et al., 1997) and hypothalamic nuclei (Schrader and Tasker, 1997).   
Increase in neuronal excitability via activation of group I mGluRs is primarily 
through modulation of K+ channels. Specific activation of group I mGluRs induces net 
inward currents by inhibiting K+ channel conductance in neurons in the hippocampus 
(Gereau and Conn, 1994) and hypothalamus (Schrader and Tasker, 1997). For instance, 
K+ channels are a major target of mGluRs, and many diverse types of K+ channels are 
inhibited following activation of mGluRs.  Activation of mGluR has been shown to block 
the  IAHP, (IAHP is outward K+ current with slowly activating and inactivating (~2s) 
kinetics) and thereby reduce accomonnodation of spike firing in hippocampal CA1 
pyramidal cells, CA3 inhibitory cells, the dentate gyrus, cultured cerebellar Purkinje cells 
and basolateral amygdaloid nucleus.  The mGluR-mediated inhibition of IAHP was found 
to be G-protein dependent. 
Activation of group I mGluRs have also been shown to modulate voltage-gated 
calcium channels (VGCCs)(Lester and Jahr, 1990; Swartz and Bean, 1992; Sahara and 
Westbrook, 1993; Swartz et al., 1993; Chavis et al., 1995; Sung et al., 2001).  Alterations 
in VGCCs can occur either presynaptically (Gereau and Conn, 1994), consequently 
changing vesicular release probability, or postsynaptically (Lester and Jahr, 1990), 
leading to changes in intracellular calcium levels.  For instance, Chavis et al found that 
activation of mGluRs leads to facilitation of the L-type Ca2+ channels (Chavis et al., 
1995; Chavis et al., 1996). Although mGluR dependent modulation of channels has been 
shown to be a consequence of direct G-protein linked action, for example, inhibition of 
Ca2+ cannels, many other effects occur as a result of activation of intracellular messenger 
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pathways.  Group I in contrast to group II mGluRs can use several distinct signal 
transduction pathways to inhibit Ca2+ channels, both Ca2+ intracellular-independent and -
dependent mechanisms (McCool et al., 1998).  
However, in addition to the postsynaptic modulation of synaptic transmission by 
alteration of neuronal excitability, group I mGluRs have been shown to function 
presynaptically.  One example is in the hippocampus, at the level of the synapses between 
Shafer collaterals and CA1 pyramidal cells.  Two groups report an increase in paired 
pulse facilitation, suggested a decrease in vesicular release probability (Gereau and Conn, 
1994; Fourgeaud et al., 2004).  Consistent with the reported presynaptic function, 
immunochemical data shows that mGluR5 is on axon terminals at these synapses (Balazs 
et al., 1997).   
 
Group I MGluRs and Plasticity 
Group I mGluRs have been shown to potentiate either NMDAR (Fitzjohn et al., 
1996; Pisani et al., 1997; Attucci et al., 2001) or AMPAR mediated responses (O'Connor 
et al., 1995; Ugolini et al., 1999).  However, a major function of group I mGluR 
activation is to produce a persistent weakening of glutamatergic transmission at synapses 
in the CNS.  There appear to be at least two mechanisms through which this is 
accomplished.  One involves the recruitment of endocannabinoid signaling and 
presynaptic alterations, and has been observed in the dorsal and ventral striatum 
(Gerdeman and Lovinger, 2001; Gerdeman et al., 2002; Robbe et al., 2002; Robbe et al., 
2003).  A second major mechanism is through endocannabinoid-independent signaling 
mechanisms (Rouach and Nicoll, 2003), and has been heavily studied in the hippocampus 
 40
and cortical regions (Huber et al., 2000; Hannan et al., 2001; Huber et al., 2001).  Both 
presynaptic (Gereau and Conn, 1994) and postsynaptic mechanisms (Snyder et al., 2001) 
have been described for endocannabinoid independent forms of group I mGluR LTD.    
The mitogen-activated protein kinase pathway is another downstream effector of 
group I mGluRs that is activated in brain regions known to be involved in drug addiction 
following administration of abused drugs (Huber et al., 2000; Valjent et al., 2001; Valjent 
et al., 2004).  Both the cannabinoid and ERK pathways will be discussed in a later 
section.  
 
Group I MGluRs can alter IGluR Function 
 Group I mGluRs also act to modulate iGluRs.  The potentiation of excitatory 
responses can be explained by an mGluR-mediated membrane depolarization that 
increases cell excitability (Xiao et al., 2001).  PKC, which is triggered by activation of 
Group I mGluRs, has been proposed to mediate the potentiation of iGluR responses 
(Ugolini et al., 1999; Skeberdis et al., 2001; Liang et al., 2005).  PKC phosphorylates 
NMDA and AMPA receptors (Roche et al., 1996). The activation of PKC by mGluRs 
might therefore modulate the phosphorylation state of these two ionotropic receptors, 
resulting in a potentiation of the response.  
As mentioned in the AMPA receptor section above, activation of group I mGluRs 
can lead to a removal of AMPA receptors from the membrane resulting in a depression of 
synaptic transmission (Snyder et al., 2001). More specifically, following activation of 
group I mGluRs there is a reduction in the density of postsynaptic AMPARs and the 
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number of synapses (Tanaka et al., 2005).  Redistribution of AMPARs has also been 
reported following group I mGluR activation (Xiao et al., 2001). 
 
Group II MGluRs 
Group II mGluRs (mGluR2/3) are widely distributed throughout the CNS, where 
they exhibit moderate to high expression in brain regions that are commonly associated 
with anxiety disorders, including the hippocampus, PFC and amygdala (Swanson et al., 
2005). MGluR2 is generally localized at the periphery of the presynaptic terminal 
suggesting a role for these receptors at instances of spillover of glutamate beyond the 
synaptic cleft in response to repetitive stimulation.  By contrast, mGluR3 is more 
diversely localized including both pre- and postsynaptic localization on neurons, as well 
as localization on certain glial cells (Ohishi et al., 1995; Shigemoto et al., 1996; 
Mannaioni et al., 2001; Poisik et al., 2003). Immunohistochemical data shows mGluR2 
and mGluR3 are expressed in neuropil of the BNST (Tamaru et al., 2001).  
Group II mGluRs most commonly function presynaptically to decrease the 
probability of synaptic vesicle release (Gereau and Conn, 1994), but at multiple synapses 
within the CNS postsynaptic mechanisms have been reported (Heinbockel and Pape, 
2000; Otani et al., 2002).  Voltage-dependent Ca2+ channels are likely to be involved in 
the presynaptic inhibition mediated by mGluRs (Anwyl, 1999). Additionally, it has been 
suggested that K+ channels mediate some of the effects induced by activation of group II 
or III mGluRs (Anwyl, 1999). 
LY354740 is a potent and very selective agonist (up to 1 µM) at mGluR2 and 3 
with an EC50 of 10 50 nM in the rat cortex, hippocampus and striatum, and 10 or 30 nM 
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in cells expressing recombinant mGluR2 or mGluR3, respectively (Fitzjohn et al., 1998). 
LY341495 is an antagonist of mGluRs, with nanomolar potency against group II mGluRs 
and micromolar potency against group III mGluRs (Fitzjohn et al., 1998). 
LTD can be induced by activation of group II mGluRs in various brain regions 
(Otani et al., 1999; Man et al., 2000; Kahn et al., 2001; Kawasaki et al., 2004) .  For 
example, group II mGluR LTD has been shown presynaptically in the BLA (Man et al., 
2000), the nucleus accumbens (Robbe et al., 2002) and the striatum (Lovinger and 
McCool, 1995; Kahn et al., 2001).  In contrast, it was shown that stimulation of thalamic 
inputs to the lateral nucleus of the amygdala induces a group II mGluR mediated 
postsynaptic LTD (Heinbockel and Pape, 2000).  Additionally, in the dentate gyrus and 
the medial PFC it was found that group II mGluR activation induced a postsynaptic LTD 
that was PKA and PKC dependent (Otani et al., 2002; Kawasaki et al., 2004).  
 
Group III MGluRs 
 Like group II mGluRs, group III mGluRs are coupled to inhibition of cAMP 
production, and modulation of ion channels (Gereau and Conn, 1994).  However, in 
contrast to the other groups, group III mGluRs are primarily located at presynaptic active 
zones at the axon terminal (Shigemoto et al., 1996; Lujan et al., 1997).  
 As with the group II mGluRs, the group III mGluRs inhibit neurotransmitter 
release. Unfortunately, there are few pharmacological tools with the desired receptor 
subtype selectivity ideal for testing the significance of the subtypes of group III mGlu 
receptors.  L-AP4, the most commonly used selective group III agonist has a high affinity 
for mGluR4/6/8 and a low affinity for mGluR7 (O'Hara et al., 1993; Cartmell and 
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Schoepp, 2000).  DCPG, a more recently described group III mGluR agonist, is a 
relatively specific mGluR8 agonist (Linden et al., 2003).  
 While there is no functional data on the role of the group III mGluRs in the BNST 
mGluR7 but not mGluR4 mRNA has beend detected in the BNST  (Ohishi et al., 1995). 
 
MGluRs; Implications in Drug Addiction and Stress/Anxiety 
 
Group I MGluRs in Stress/Anxiety 
 Agonists and antagonists of mGluRs show anxiolytic-like properties in animal 
models (Chojnacka-Wojcik et al., 1996; Bond et al., 1997; Chojnacka-Wojcik et al., 
1997; Monn et al., 1997; Klodzinska et al., 1999).  Important to the stress response is the 
activation of the HPA axis by group I mGluRs.  Specifically, group I mGluRs agonists 
and antagonists given intracerebroventricularly have been shown to cause a long lasting 
enhancement of serum corticosterone levels in rats (Johnson et al., 2001).  Several studies 
within the last 5 years examined the anxiolytic potential of the mGluR5 antagonists, 
MPEP and MTEP, and found them to be effective in attenuating anxiolytic-like behaviors 
in a range of anxiety tests (Carlezon et al., 1998; Klodzinska et al., 2000; Chojnacka-
Wojcik et al., 2001; Spooren et al., 2001; Tatarczynska et al., 2001; Pilc et al., 2002; 
Busse et al., 2004; Wieronska et al., 2004).  For example, oral administration of MPEP 
has anxiolytic-like effects on behavior in response to fear potentiated startle (Schulz et 
al., 2001).  Spooren et al (2000) showed that MPEP significantly increased open arm time 
in the elevated plus maze and increased the time of social contact in the social 
exploration test in rats (Spooren et al., 2001).  Activation of group I mGluRs by 
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intracerebroventricular (icv) administration of DHPG has also been shown to attenuate 
baclofen-mediated anxiety behaviors in rats (Car et al., 2000).  
 The behavioral effects of mGluR activation/inhibition on stress related behaviors 
in brain regions previously shown to be involved in the stress pathway have been studied.  
For instance, it was found that intrahippocampal administration of a group I mGluR 
antagonist or a group II mGluR agonist results in anxiolytic-like behaviors (Tatarczynska 
et al., 2001).  Additionally, it was found that ICV administration group I mGluR agonists 
or antagonists cause a long-lasting enhancement of serum corticosterone levels in rats 
(Johnson et al., 2001).  This suggests group I mGluRs play a role in modulation of the 
stress pathway. 
 
Group I MGluRs and Addiction 
 mGluR5 has been implicated in cocaine-related behaviors, most profoundly 
mGluR5-null mutant mice are insensitive to the locomotor-stimulating and rewarding 
properties of cocaine(Chiamulera et al., 2001). Consistent with this effect, the mGluR5 
specific antagonist, MPEP, has been show to attenuate cocaine mediated behavioral 
effects, including cue induced relapse to cocaine seeking (Chiamulera et al., 2001; Herzig 
and Schmidt, 2004; Backstrom and Hyytia, 2005).  Additionally, Homer proteins, as well 
as another scaffolding protein, PSD95, which are involved in linking mGluRs to the PSD 
are modified by in vivo cocaine administration (Hu et al., 1999; Yao et al., 2004; 
Swanson et al., 2005).  More specifically, deletion of either Homer1 or Homer2 results in 
an increase in sensitivity to cocaine similar to animals withdrawn from cocaine 
(Szumlinski et al., 2004).  The authors suggest the similarities in cocaine related 
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behaviors in Homer KO mice and the effects of chronic cocaine treatment implicate 
Homer in regulating addiction to cocaine. 
MGluR alterations in drug related paradigms could be due to interactions with the 
monoaminergic signaling systems.  Page et al., (2005) performed an interesting set of 
experiments in which they looked at the effects of MPEP on the levels of NE in the 
frontal cortex during a behavioral stress test (Page et al., 2005).  Interestingly, they 
suggest that blockade of mGluR5 attenuates stress-induced NE efflux.  As NE signaling 
in the BNST is critical for stress induced reinstatement (Leri et al., 2002) this begs the 
question as to whether there is an interaction between the noradrenergic system and 
perhaps the dopaminergic system with group I mGluRs in the BNST.   
At the level of synaptic transmission endocannabinoid-dependent group I mGluR-
induced LTD is disrupted in the ventral striatum in animals previously exposed to 
cocaine, suggesting that alterations in this form of plasticity may play a role in cocaine-
induced alterations in animal behavior (Swanson et al., 2001; Fourgeaud et al., 2004).   
 
Group II and III MGluRs in Stress/Anxiety 
 Excessive glutamatergic transmission has been implicated in neurological 
disorders such as stress and anxiety.  It is therefore not surprising that activation of Gi/o-
linked group II and III metabotropic glutamate receptors (mGluRs) produce anxiolytic-
like effects in behavioral paradigms designed to test stress/anxiety (Fitzjohn et al., 1998; 
Klodzinska et al., 1999; Pilc et al., 2000).  A broad spectrum of behavioral tests 
demonstrates the anxiolytic-like effects after oral administration of a group II mGluR 
agonist LY 354740 (Helton et al., 1998).  More specifically, LY364740 produced a 
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lasting, dose-dependent blockade of fear-potentiated startle response in rats, with a near 
complete blockade in fear-enhanced startle with no effects on basal startle (Helton et al., 
1998).  Activation of group II mGluRs was shown to have anxiolytic-like properties in 
another behavioral paradigm used to study stress, the elevated plus maze.  LY354740 
increased the time spent in the open arm of the elevated plus maze (Helton et al., 1998).  
Collectively, these findings indicate that activation of group II mGluRs might function to 
maintain brain excitability in anxiety states by modulating excitatory neurotransmission 
at specific synapses within the stress pathway, including the BNST. 
 Determining the roles of group III mGluRs in stress/anxiety has proven more 
difficult due to lack of brain permeable pharmacological agents acting at these receptors.  
To begin to study the roles of group III mGluRs by pharmacological manipulation 
researchers have had to inject these compounds into the CNS.  Injection of the group III 
agonist L-SOP resulted in an anxiolytic-like effect in the vogel conflict test (Tatarczynska 
et al., 2001)  However, genetic manipulations have given us insight into the functions of 
these receptors in these disorders.  For instance, mGluR7 is abundant in brain regions 
known to be critical for manifestations of the stress response, such as the hippocampus, 
amygdala, locus coeruleus and the BNST (Kinoshita et al., 1998).  Studies on the 
mGluR7 KO mice suggest this receptor may play a role in the integration of the stress 
response.  MGluR7 KO mice have been reported to show anxiolytic-like activity in the 
elevated plus maze, staircase test, light–dark box and stress-induced hyperthermia models 
(Cryan et al., 2003).  Interestingly, in contrast to the mGluR7 KO animals, mGluR8 KO 
mice have an increase axiolytic-like behavior in the elevated plus maze (Linden et al., 
2002).   
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 Group II and III MGluRs in Addiction  
 Changes in glutamatergic transmission mediated by group II mGluRs have also 
been observed in the NAc of rats previously exposed two weeks earlier to repeated 
systemic injections of amphetamine, indicating that these receptors may potentially 
contribute to the expression of sensitization by amphetamine as well as other 
psychomotor stimulants (Kim and Vezina, 1999; Kim et al., 2005).  Additionally, 
injection of a group II mGluR agonist during the preexposure to VTA amphetamine 
completely blocked sensitization (Kim and Vezina, 1998).  In other words, in 
combination with the well demonstrated role of group II mGluRs in synaptic plasticity, 
the Vezina group suggests the induction and expression of locomotor plasticity (a form of 
behavioral sensitization) involves group II mGluR-DA interactions. By injecting the 
group III mGluR agonist L-AP4 into the striatum it has also been shown that activation of 
these receptors can inhibit the acute locomotor enhancement by cocaine (Mao and Wang, 
2000). 
Systemic injections of LY379268 or other mGluR2/3 agonists attenuate several 
behavioral effects of abused drugs (Kenny and Markou, 2004), including opiate 
withdrawal symptoms (Vandergriff and Rasmussen, 1999), amphetamine-induced 
locomotor sensitization (Vezina, 2004), discriminative cue-induced reinstatement of 
cocaine seeking (Baptista et al., 2004) and heroin seeking (Bossert et al., 2005).  
Consistent with a decrease in levels of Gαi in NAc following administration of drugs of 
abuse discussed earlier, group II mGluR LTD in the NAc is attenuated in morphine 
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withdrawn animals (Robbe et al., 2002).  Another Gαi-linked receptor implicated in drug 
addiction is the cannabinoid receptor 1 (CB1R).   
 
Cannabinoids 
Marijuana (cannibis sativa) is one of the oldest and most widely used drugs in the 
world.  Δ9-tetrahydrocannabinol (Δ9-THC) is the primary psychoactive ingredient of 
cannabis.  Δ9-THC along with other naturally occurring and synthetic cannabinoids, binds 
to two separate GPCRs:  cannabinoid receptor 1 (CB1) and CB2 (Matsuda et al., 1990; 
Gerard et al., 1991; Munro et al., 1993).  CB1 receptors are found predominantly in the 
CNS and the periphery while CB2 receptors are located mostly within the immune 
system (Zimmer et al., 1999).  Two candidate endocannabinoids, monoacyl-glycerol 2-
arachidonoylglycerol (2-AG) and the fatty acid amide N-arachidonoyl ethanolamin 
(anandamide) along with these receptors make up the endogenous cannabinoid 
(endocannabinoid) system.  2-AG is thought to be produced by a largely calcium 
independent manner downstream of PLC activity, while anandamide production and 
release appears to be more calcium dependent.   
This cannabinoid system has been proposed to play a role in pain (Calignano et 
al., 1998), cognition (Marsicano et al., 2002), drug dependence (Varma et al., 2001) and 
excitotoxicity (Marsicano et al., 2003).  The CB1R is one of the most highly expressed 
neuromodulatory receptors in the brain and is activated by the endogenous lipid signaling 
molecules, anandamide and 2-AG (Wilson and Nicoll, 2002). Cannabinoid signaling 
differs from traditional synaptic signaling in that endogenous cannabinoids can function 
as retrograde synaptic messengers. They are released from postsynaptic neurons and 
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travel in a retrograde manner across synapses, activating CB1 receptors at presynaptic 
terminals.  Consequently, CB1 receptors, which are coupled to inhibitory G-proteins, act 
to suppress neurotransmitter release. CB1 activation suppresses neurotransmitter release 
by decreasing the local release probability of synaptic vesicles (Wilson and Nicoll, 2002). 
Of great interest in the mGluR field was the finding that endocannabinoid 
synthesis can be triggered by activation of group I mGluRs.  Retrograde signaling 
through the cannabinoid system helped explain biophysical evidence suggesting a 
presynaptic change in probability of neurotransmitter release with immunochemical data 
suggesting group I mGluRs are localized almost exclusively to postsynaptic structures 
(Baude et al., 1993; Lujan et al., 1997). Interestingly, it was shown that cannabinoid 
receptor activation leads to a cascade involving downregulation of PKA activity that 
leads to an increase in ERK phosphorylation (Walker et al., 2003).  The ERK pathway is 
also implicated as a downstream target of group I mGluR activation. 
 
Extracellular Signal-Regulated Kinase (ERK) 
The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) pathway is a signaling cascade that plays a crucial role in a variety of cell 
regulatory events (Chen et al., 2001). The role of ERK signaling in cell proliferation, 
differentiation, and survival is well established, but emerging evidence has suggested an 
involvement of ERK signaling in long-term synaptic changes and behavior (Orban et al., 
1999; Mazzucchelli and Brambilla, 2000; Adams and Sweatt, 2002). In neurons, ERK 
activation has been shown to be involved in processes associated with synaptic 
remodeling and long-term changes in synaptic efficacy.  These processes include protein 
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synthesis, changes in gene expression, dendritic spine stabilization, modulation of ion 
channels, and receptor insertion (Figure 5; (Sweatt, 2004).   
The ERK cascade is activated by a variety of extracellular agents, which include 
growth factors, hormones, and neurotransmitters (Chen et al., 2001). The best described 
pathway of ERK activation is stimulation in response to activators of tyrosine kinase 
family receptors.  In brief, tyrosine kinase receptors are bound by activators and stimulate 
the GTPase Ras via the scaffolding protein Grb2 and the guanine nucleotide exchange 
factor Sos.  Ras then activates the ubiquitous Raf-1 pathway, the first of a series of three 
kinases that characterize signaling in the MAPK superfamily of enzymes.  The classic 
MAPK signaling pathway begins with a MAP kinase kinase kinase (Raf-1 or B-Raf).  
Serine/threonine phosphorylation by either of these kinases leads to activation of MAP 
kinase kinase (MEK).  MEK, in turn, is a dual specificity kinase that phosphorylates both 
threonine and tyrosine residues on MAPK (ERK1/ERK2).  
ERK1/2 activities are primarily regulated at two levels, one at phosphorylation, 
and the other at translocation from the cytoplasm to the nucleus. The former is controlled 
by the balance of kinase and phosphatase activities. Two phosphatases, MAP kinase 
phosphatases (MKPs) with dual specificities for tyrosine and serine/threonine (Muda et 
al., 1996) and protein tyrosine phosphatases (PTP-SL) with a specialty for threonine 
(Pulido et al., 1998; Zuniga et al., 1999), have been reported to dephophosphorylate and 
therefore inactivate ERK1/2. When ERK1/2 is activated, the phosphorylation promotes 
ERK1/2 to dimerize and then ERK1/2 is rapidly translocated from the cytoplasm to the 
nucleus (Robinson and Cobb, 1997; Khokhlatchev et al., 1998). However, in some cases, 
ERK1/2 can still be detected in the cytoplasm. Cytoplasmic retention of the ERK1/2 is 
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controlled by cytoplasmic anchor proteins such as MEK1/2 (Fukuda et al., 1997), β-
arrestin (Dale et al., 2002), or by the dephosphorylation with MKP3 (Muda et al., 1996; 
Muda et al., 1996) and PTP-SL (Zuniga et al., 1999) 
ERK serves as an important point of convergence for the PKC and PKA 
pathways. PKC regulates ERK activity through an interaction with either Ras or Raf-1 
leading to activation of MEK and consequently ERK (Sweatt, 2001; Adams and Sweatt, 
2002).  Additionally, it was discovered that DAG, another second messenger product of 
PLC activity, is capable of activating ERK independent of PKC activation (Ebinu et al., 
1998; Kawasaki et al., 1998).   Phosphorylation of both tyrosine and threonine residues in 
MAP kinases, which are found in the activation segment of the kinase domain, is 
essential for full kinase activity of ERK.  In turn, ERK targets only serine and threonine 
residues that are closely followed by one or more prolines in the ERK recognition motif.   
To date, evidence has suggested that ERK2 is the primary ERK isoform (Sweatt, 
2004).  First, ERK2 is the predominant isoform expressed in the hippocampus and 
amygdala.  Second, NMDAR-dependent synaptic plasticity in the hippocampus is normal 
(Selcher et al., 2001) or only subtly altered in the dorsal striatum (Mazzucchelli et al., 
2002) in ERK1 knockout mice.  Third, multiple labs have suggested that stimuli that 
promote these forms of synaptic plasticity may selectively activate ERK2 (Adams and 
Sweatt, 2002). 
At present, very little is known about the distinctive roles of the ERK1 and ERK2 
isoforms, as they are highly homologous (Chen et al., 2001).  However, several studies, 
primarily in non-neuronal systems, have identified proteins and/or drugs that produce or 
facilitate selective activation of ERK1 versus ERK2.  For example, MEK-binding partner 
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1 (MP1) selectively facilitates ERK1 activation and binds with considerable selectivity to 
ERK1 over ERK2 (Schaeffer et al., 1998).  While little information exists for substrates 
differentially phosphorylated by ERK1 and ERK2, data from knockout mice point to 
differences in function.  For example, while ERK1 knockout mice are viable and fertile 
(Pages et al., 1999; Selcher et al., 2001; Pages and Pouyssegur, 2004), targeted disruption 
of ERK2 produces a lethal mutation (Adams and Sweatt, 2002).  Further, while much 
pharmacological evidence suggests that the MAP kinase signaling cascade plays an 
important role in NMDA-receptor dependent synaptic plasticity and learning and 
memory, hippocampal and amygdala based learning are unimpaired in ERK1 knockout 
mice (Selcher et al., 2001), and NMDA receptor-dependent plasticity is either normal 
(Selcher et al., 2001), or altered in complex ways in ERK1 null mice (Mazzucchelli et al., 
2002). 
Effectors through which these proteins kinase cascades act include proteins that 
regulate gene expression (cAMP-response element binding protein (CREB) and histone 
acetyltransferases (HAT)), as well as the voltage-gated potassium channel Kv4.2 (Adams 
and Sweatt, 2002).  The last target represents a mechanism by which ERKs can regulate 
neuronal excitability.  Other candidate molecules also exist (glutamate receptors, calcium 
channels, phosphatases, cytoskeletal proteins, and protein synthesis machinery).  
Since English and Sweatt first provided evidence that ERK signaling is involved 
in plasticity by using the MEK inhibitor PD 98059 to block LTP induction in the 
hippocampus, much emphasis has been placed on the role of this signaling cascade in 
learning and memory, and in glutamatergic synaptic plasticity at a variety of synapses 
(Orban et al., 1999; Adams et al., 2000; Mazzucchelli and Brambilla, 2000; Adams and 
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Sweatt, 2002; Mazzucchelli et al., 2002; Gallagher et al., 2004; Sweatt, 2004).  In 
particular, MEK inhibitors block the induction of several forms of NMDA-receptor 
dependent LTP and LTD throughout synapses of the hippocampus and the amygdala (for 
review see Sweatt, 2004).  NMDAR-independent forms of LTD are also blocked by 
MEK inhibitors.  Importantly, group I mGluR LTD in the hippocampus and cerebellum is 
dependent on ERK activation (Kawasaki et al., 1999; Gallagher et al., 2004). 
 
ERK and Drug Addiction 
A more recent, growing literature indicates that the ERK signaling cascade plays 
a critical role in behavioral alterations produced by psychostimulants.  Inhibitors of the 
ERK signaling cascade administered in vivo reduce psychostimulant mediated behavioral 
sensitization (Valjent et al., 2005).  It has also been suggested that ERK activation is 
involved in the incubation of cocaine craving in a region-specific manner (Lu et al., 
2005).  For instance, ERK signaling is necessary for VTA-BDNF stimulated long term 
enhancement of cocaine seeking during withdrawal (Lu et al., 2004).  And importantly, in 
vivo psychostimulant administration produces activation of ERK in the reward circuitry 
including strong activation within the BNST (Valjent et al., 2000; Valjent et al., 2004).  
In addition to being involved in the rewarding properties of cocaine (Valjent et al., 2000), 
morphine, nicotine, cocaine and alcohol administration alters ERK activity (Narita et al., 
2002; Sanna et al., 2002; Brunzell et al., 2003; Zhang et al., 2004).  Also, consistent with 
a role of ERK in synaptic transmission in the BNST, addictive drugs activate ERK in the 
lateral BNST (Valjent et al., 2004).   
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Summary 
There are many implications for mGluR function and the BNST in 
pathophysiological conditions such as stress/anxiety and drug addiction.  Therefore, 
mGluRs and signal transduction mechanisms activated by these receptors within the 
BNST are potential targets for pharmacological treatment of drug related behaviors (stress 
induced reinstatement) and stress/anxiety conditions.   
 
Hypothesis 
Glutamate acts to modulate neuronal transmission in the BNST via mGluRs by recruiting 
signaling cascades previously shown to be involved in stress and addiction. 
 
Specific Aims 
1.  Characterization of group II and/or III mGluR function as well as synaptic locus on 
excitatory transmission in the BNST. 
2.  Investigation of function, synaptic locus, downstream effectors and a behavioral 
correlate to drug addiction of group I mGluRs in the BNST. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Animals 
Male C57Bl/6j mice (5-10 weeks old, Jackson Laboratories), CB1 receptor (-/-) males 5-
6 weeks of age, or ERK1 receptor (-/-) males 5-6 weeks of age, both of which were on a 
C57Bl/6j background, were used.   
 
Brain Slice Preparation 
For interface chamber recordings, the brains were quickly removed and placed in ice-cold 
artificial cerebro-spinal fluid (ACSF) (in mM: 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 
NaH2PO4, 10 glucose, and 26 NaHCO3).  Slices 300 μm in thickness were prepared using 
a vibratome (Leica).  Rostral slices containing anterior portions of BNST (Bregma 0.26 
mm to 0.02 mm) (Franklin and Paxinos, 1997) were identified using the internal capsule, 
anterior commissure, fornix and stria terminalis as landmarks as previously described 
(Egli and Winder, 2003; Weitlauf et al., 2004; Egli et al., 2005).  Slices were then 
transferred to either an interface recording chamber (field potential recordings, ~28°C ), a 
submerged recording chamber (whole-cell patch clamp recordings, 24-25°C) or a 
submerged holding chamber (25°C) where they were perfused with oxygenated (95% 
O2/5% CO2) ACSF at a rate of 2 mL/minute.  Slices were allowed to equilibrate in 
normal ACSF for one hour before experiments began.  
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Extracellular Field Potential Recordings
     Low resistance (2-3 MΩ) extracellular electrodes were pulled with borosilicate glass 
on a Flaming-Brown Micropipette Puller (Sutter) and were filled with ACSF.  
Stimulating electrodes consisted of twisted, insulated nichrome bipolar wire.  Stimulating 
electrodes were placed on the dorsal anterolateral BNST (dBNST) border of the internal 
capsule approximately 200-500 µm dorsal to the anterior commissure.  Field potential 
responses were evoked at a frequency of 0.05Hz using a stimulus range of 5-15 V at a 
duration of 100-150 µs.  Experiments were performed in a heated (~28°C) interface-style 
recording chamber (Fine Science Tools) as previously reported (Weitlauf et al., 2004; 
Grueter and Winder, 2005).  All recordings were performed in the presence of 25 μM 
picrotoxin.   Data points are represented as averages of the peak amplitude at 1 minute 
intervals. 
 
Local Stimulation in the dBNST Yields an Excitatory Response 
 Consistent with previous results (Weitlauf et al., 2004), as shown in Figure 6, 
brief, local, single pulse stimulation (50-100 µs) in dBNST from 6-10 week old male 
C57Bl6/J mice yields a short latency extracellular waveform in an interface chamber 
which typically includes a biphasic negative potential in the presence of 25 µM 
picrotoxin (Figure 6).  The first downward deflection (referred to as N1) of the biphasic 
peak is abolished by the sodium channel blocker, tetrodotoxin (TTX, 1 µM; Figure 6). 
Thus, the N1 is thought to be indicative of an axonal response and to reflect the number 
of axons/cells directly stimulated in the field.  The second peak (referred to as N2) also is 
abolished by TTX, but in addition is sensitive to CNQX, an AMPA/kainate receptor  
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Figure 6.  Characterization of field potential responses in BNST.  a.  The time course 
of the effects of TTX (1 µM for 15 min, n=5) on the N1 and N2 of the BNST field 
potential.  Inset, representative traces of a BNST field potential pre- and post TTX (1 
µM) application.  b.  The time course of the effects of CNQX (10 µM for 15 min, n=6) on 
the N1 and N2 of the BNST field potential.  Inset, representative trace of a BNST field 
response pre- and post-CNQX (10 µM) application.   
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antagonist, suggesting that it is driven by excitatory glutamatergic transmission (Figure 
6). 
Whole-Cell Voltage-Clamp Recordings 
     Slices were prepared as above except the dissection solution was a low Na+/high 
sucrose solution.  Recordings were performed in a submerged chamber continuously 
perfused at a rate of 2 ml/minute with oxygenated ACSF (24-25°C).  Electrodes of 3.0-
5.0 MΩ were pulled on a Flaming-Brown Micropipette Puller and were filled with (in 
mM): K+ gluconate or Cs gluconate (135), NaCl (5), HEPES (10), EGTA (0.6), ATP (4), 
GTP (0.4) and biocytin (0.1%).  Effects of mGluR ligands on glutamatergic transmission 
obtained with these two internal solutions were comparable and therefore pooled.  All 
cells recorded from were voltage-clamped at -70 mV.  Excitatory post synaptic currents 
(EPSCs) of 100-400 pA were acquired by a Multiclamp amplifier (Axon Instruments), 
digitized and analyzed via pClamp 9.0 software (Axon Instruments). Input resistance (K+ 
140-800 MΩ; Cs+ 400-5000 MΩ), holding current, and access resistance (12-45 MΩ) 
were all monitored continuously throughout the duration of the experiments (see Figure 
8a).  Experiments in which changes in access resistance were greater than 20% were not 
included in the data analysis.  Stimulating electrodes and their placement were identical 
to field potential recordings.  Stimulus intensity ranged from 6-30 V with a 100 µs 
duration.  Events were recorded at a frequency of 0.17 Hz.  Data is represented as a 1 
minute average of the peak amplitudes. 
Whole-cell patch clamp recordings were acquired in cells from the same region of 
the dBNST as the field potential recordings.  The configuration recording differed in that 
whole-cell patch clamp recordings were performed in a submerged chamber.  Current- 
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Figure 7.  Characterization of synaptically evoked EPSCs in the BNST.  
 a.  Representative trace of an I-V relationship of a BNST neuron.  Cell was voltage 
clamped at -70 mV and stepped in 10 mV intervals from -100 to -20 mV.  Scale indicates 
100 pA and 2 msec.  b.  I-V plot of EPSC.  Inset represents traces at -70 and +40 mV.  c.  
Stability of evoked EPSCs in the BNST (n=4).  e.  Time course of effects of CNQX on 
EPSCs in the BNST (n=3). 
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voltage relationships obtained from these neurons (Figure 7) are consistent with those 
previously reported (Rainnie, 1999; Egli and Winder, 2003).  Synaptic stimulation in the 
presence of 25 µM picrotoxin, at a holding potential of -70mV elicited an EPSC (Figure 
7). Unless otherwise reported, cells were allowed to equilibrate at least 10 minutes after 
whole-cell configuration before baseline was recorded.  This EPSC had a reversal 
potential of near 0 mV when corrected for junction potential (Figure 7), was stable for 
long periods of time (Figure 6), and was abolished by CNQX at -70mV (Figure 7).  The 
EPSC under basal stimulation is unaltered in the presence of the NMDA antagonist DL-
AP5 (Data not shown).  These data indicate that the postsynaptic currents elicited by a 
brief stimulus are primarily mediated by non-NMDA glutamate receptor subtypes.   
A paired-pulse ratio (PPR) was acquired by applying a second stimulus of equal 
intensity 50 ms after the first stimulus.  The magnitude of the facilitation that occurs in 
response to paired-pulse stimulation, a measure that has been shown to change in 
response to alteration in release probability, was compared before, during and after drug 
application.   An alteration in the paired pulse ratio, that is the amplitude of the second 
pulse over the first pulse, suggests a presynaptic site of action.    
Miniature EPSCs were collected at a holding potential of -90mV in the presence 
of 1 μM TTX.  2 minute blocks of events were analyzed using Minianalysis software 
(Synaptosoft, Decatur, Georgia) with detection parameters set at greater than 5 pA 
amplitude and less than 3 ms rise time.   All events were verified by eye. 
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Drug Application
     All experiments were performed in the presence of picrotoxin (25μM).  Where 
indicated in the text, the following drugs were bath applied: tetrodotoxin (TTX, 1 µM) 
and 6-Cyano-7-nitroquinoxaline-2,3-dione disodium salt (CNQX, 10 µM) were 
purchased from Sigma-Aldrich (St. Louis, MO).  (2S,2’R,3’R)-2-(2’,3’-
Dicarboxycyclopropyl)glycine (DCG-IV, 1 µM), L-(+)-2-Amino-4-phosphonobytyric 
acid (L-AP4), DL-2-Amino-5-phosphonovaleric acid (APV, 10 µM), (2S)-2-Amino-2-
Figure-3-(xanth-9-yl) propanoic acid, (LY 341495, 1 µM), and (S)-3,4-
Dicarboxyphenylglycine (DCPG, 30µM) were purchased from Tocris.  Dimethyl 
Sulfoxide (DMSO) was the carrier for picrotoxin (0.02% v/v).  (1S,2S,5R,6S)-2-
aminobicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY 354740) was a gift from Dr. 
Darryle Schoepp (Eli Lilly). 
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CHAPTER III 
 
 
   
GROUP II AND III METABOTROPIC GLUTAMATE RECEPTORS SUPPRESS 
EXCITATORY SYNAPTIC TRANSMISSION IN THE DORSOLATERAL BED 
NUCLEUS OF THE STRIA TERMINALIS 
 
 
Introduction 
 Behavioral studies, both in rodent models of anxiety (Helton et al., 1998; 
Klodzinska et al., 1999; Linden et al., 2002; Tizzano et al., 2002; Linden et al., 2003) and 
in humans (Fitzjohn et al., 1998; Grillon et al., 2003) suggest that group II and III mGluR 
ligands may represent useful approaches to treat anxiety.  These receptors regulate 
glutamatergic transmission in several different brain regions, in many cases inhibiting 
transmission (Heinbockel and Pape, 2000; Man et al., 2000; Kahn et al., 2001; Otani et 
al., 2002; Robbe et al., 2002), and in other cases enhancing transmission (Evans et al., 
2000; Rush et al., 2001; Wu et al., 2004).  Group II and III mGluRs have been shown to 
function in brain regions involved in stress responses. For instance, group II mGluRs 
provide tonic regulation of glutamatergic transmission in the hypothalamic-pituitary-
adrenocortical axis (Scaccianoce et al., 2003) and  inhibition of glutamatergic 
transmission in the PFC (Otani et al., 2002),  Group III mGluRs induce a long-lasting 
potentiation of glutamatergic transmission in the BLA (Neugebauer et al., 1997) and 
inhibit glutamatergic transmission in the PVN (Schrader and Tasker, 1997).  Both group 
II and group III mGluRs have been shown to inhibit glutamatergic transmission in the 
central nucleus of the amygdala  (Neugebauer et al., 2000), and hippocampus (Capogna, 
2004).   
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 Immunohistochemical studies suggest expression of mGluR2, mGluR3 (Kinoshita 
et al., 1998; Tamaru et al., 2001), and mGluR7 in the BNST (Kinoshita et al., 1998) as 
well as mRNAs for mGluR7 but not mGluR4 (Kinzie et al., 1995; Ohishi et al., 1995).  
To date, the actions of mGluRs on glutamatergic transmission in the BNST have not been 
reported.  Therefore, we utilized two distinct electrophysiological methods, extracellular 
field potential and whole-cell patch clamp recordings, to determine the effect of 
activation of group II and III mGluRs on excitatory transmission in BNST.  We find that 
both group II and group III mGluRs elicit a long-lasting inhibition of excitatory synaptic 
transmission in the BNST. 
 
Results 
 
Group II MGluR Activation Inhibits Excitatory Field Potentials in the dBNST 
 
 To determine the role of activation of group II mGluRs on excitatory synaptic 
transmission in dBNST, we assessed the effects of application of specific group II mGluR 
agonists on both the extracellular N2 response and the EPSC.  To evaluate the effect of 
group II mGluR activation on the CNQX-sensitive N2 potential in dBNST slices, the 
group II mGluR agonist LY354740 (1 µM for 15 min) was bath applied in an interface 
recording chamber.  LY354740 caused a transient, reversible depression of the field 
potential to 74.8 ± 4.7% of baseline that was not associated with any changes in the N1 
response (Figure 8a).  This action was blocked by pretreatment of the slice with the 
mGluR antagonist LY341495 (1 µM, Figure 8b), which had no effect on basal 
transmission when applied alone (data not shown).  Furthermore, the effect of LY354740 
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on field recordings was mimicked by another selective group II mGluR agonist DCG-IV.  
Perfusion of DCG-IV (1µM, 15 min, in presence of DL-APV to block potential direct 
actions of the drug at NMDA receptors ) caused a reversible depression of the N2 
amplitude to 70.0 ± 3.6 % of baseline (Figure 8c).    
  
Group II MGluR Activation Inhibits Synaptically-Evoked EPSCs in the dBNST in a 
Dose-Dependent Manner 
 
 The inhibition of the field potential response observed above could be through 
mGluRs acting at a number of different levels.  To more specifically isolate glutamatergic 
synaptic transmission, we determined the effect of activation of group II mGluRs on 
voltage clamped EPSCs.  Similar to field potential results described above, brief 
perfusion of LY354740 (1µM for 5 minutes) during whole-cell voltage clamp recordings 
of dBNST neurons caused a transient depression of EPSCs.  Peak depression was 53.4 ± 
3.9 % of baseline (Figure 9a,b).  The LY354740 elicited inhibition of EPSC amplitude 
returned to baseline levels approximately 30 minutes post washout.  As shown in 
representative fashion in Figure 4A, this depression of the EPSC was not associated with 
marked changes in the holding current or input resistance (Rm).   LY354740-induced 
suppression of EPSCs was concentration-dependent, with an EC50 of ~6.0 nM (Figure 
9c). 
  
 
 
 
 
 66
  
 
 
 
 
Figure 8.  Group II activation depresses synaptic field potentials in the BNST.  Time 
course of effects of group II mGluR compounds on excitatory transmission in the BNST.  
a.  LY354740 (1 µM, 15 min, n=5) significantly reduced field potential amplitude in the 
BNST.  The effects of  LY354740 were completely reversible 30 minutes following 
washout.   b.  The effects of LY354740 (1 µM) were blocked by LY341495 (1 µM 
LY341495, n=5).  c. DCG-IV (1 µM, 15 min, in presence of 100 µM AP-5, n=5) also 
inhibits N2 responses.  Scale indicates 0.2 mV and 20 msec. 
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Figure 9.  Inhibition of EPSCs in BNST neurons by activation of group II mGluRs is  
concentration dependent. a.  Representative experiment illustrating the lack of 
postsynaptic effects and the depression of excitatory synaptic transmission by LY354740 
(1 µM, 5 min).  b.  Average results of 5 minute application of LY354740 (n=6).  c.  
Depression of synaptic transmission by LY354740 is concentration dependent (n=3-6).  
d.  The effects of LY354740 were blocked by LY341495 (n=3). 
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 Similar to field potential effects, LY341495 (1µM) blocked the depression of 
EPSCs induced by LY35740.  In the presence of LY341495, the depression induced by 
LY354740 was 101.3 ± 10.1% of baseline (Figure 9d).  These results suggest a group II 
mGluR inhibits excitatory transmission in the dBNST.  
 
Group II MGluR Activation Induces a Long Term Depression of Excitatory Transmission 
in the dBNST 
 
 At many glutamatergic synapses in the CNS, mGluR activation can recruit a 
lasting reduction in synaptic efficacy.  In particular, group II mGluR activation has been 
shown to persistently reduce synaptic efficacy at several different CNS synapses (Otani et 
al., 1999; Man et al., 2000; Kahn et al., 2001; Kawasaki et al., 2004).  While brief 
application of the group II mGluR agonist LY354740 produced only a transient 
depression of synaptic transmission, we find that more prolonged activation of the 
receptor produced a persistent depression of synaptic transmission in dBNST (Figure 
10a).  The effect is unlikely to be mediated simply by poor pharmacokinetics, as bath 
application of the antagonist LY341495 (1μM) 30 minutes following washout of the 
agonist failed to reverse the depression (Figure 10b).  This concentration of LY341495 
was sufficient to abolish the effects of LY354740 when applied immediately prior to 
agonist application (Figure 9d). 
 
Group III MGluR Activation Depresses Glutamatergic Transmission in the dBNST 
 
 To test the potential role of group III mGluRs in regulating glutamatergic 
transmission in the dBNST, we bathed slices with increasing concentrations of the group  
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Figure 10.  Group II mGluR activation induces long term depression in the BNST 
a.  Application of LY354740 (1 µM) for an extended time period (1 µM, 15 min) resulted 
in a depression of synaptic transmission that persisted in the absence of the drug (n=9).  
b.    Application of LY341495 (1 µM) 30 min post LY354740 washout fails to reverse 
depression of EPSC (n=3).   
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III mGluR agonist, L-AP4.  At the maximal concentration tested (1 mM), L-AP4 induced 
a depression of EPSC amplitude to 41.0 ± 6.9 percent of the baseline amplitude that only 
partially reversed to 69.6 ± 9.9% of baseline 40 minutes after washout (Figure 11a, c).  
No changes in postsynaptic properties were observed.  The dose-response relationship 
suggests a low potency for L-AP4, since 1mM L-AP4 did not clearly saturate the effect 
(Figure 11c).  To begin to determine which subtypes of group III mGluRs may participate 
in regulating glutamatergic transmission in dBNST, we also utilized the mGluR8 specific 
agonist DCPG.  30µM DCPG elicited a depression of EPSC amplitude to 70.4 ± 7.9 % of 
the baseline amplitude (Figure 11b). 
 
Activation of Group II MGluRs does not Enhance Group III MGluR-Mediated Inhibition 
 
 Multiple brain regions provide glutamatergic input into the dBNST, including the 
BLA, subiculum and prelimbic cortical areas.  While both group II and group III mGluR 
activation robustly inhibits EPSCs in the dBNST, neither completely abolishes the 
response.  To begin to determine whether group II and group III mGluRs act at the same 
synapses through the same mechanisms, we co-applied these agonists at the maximal 
concentrations we utilized.  Co-application of 1µM LY354740 (a saturating concentration 
based on the concentration-response curve) and 1mM L-AP4 for 5 minutes resulted in a  
depression of EPSC amplitude to 34.5 ± 7.2% (Figure 12).  The effect partially reversed 
to a magnitude of 64.9 ± 11.2% baseline.  The coapplication of LY354740 and L-AP4 did 
not significantly alter EPSCs compared with the effects of L-AP4 at the concentrations 
used (34.5 ± 7.2% vs. 41.0 ± 6.9% of baseline for LY354740 + L-AP4 and L-AP4 alone,  
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Figure 11.  Group III mGluR activation inhibits EPSCs in the BNST.  a.  1 mM L-
AP4 caused a lasting depression in synaptic transmission (n=6).  b.  Effects of 30µM 
DCPG on synaptic transmission in the BNST.  c.  Effects of 10 µM, 100 µM and 1 mM 
L-AP4 on EPSC amplitude (n=5-6). 
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Figure 12.  Group II receptor activation fails to enhance group III mediated 
inhibition of EPSCs in the BNST.  Time course of effects of LY354740 (1 µM), L-AP4 
(1 mM) and coapplication of the agonists for 5 min on EPSCs in the BNST (n=4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73
respectively; p>0.05).  Thus these data suggest that the mGluRs mediating the actions of 
these drugs may be expressed on a common set of synapses. 
 
Group II and III MGluR Depression of EPSC Amplitude is Associated with Enhancement 
of Paired-Pulse Ratios in the dBNST 
 
 To begin to determine the locus of the actions of group II and III mGluRs in 
regulating EPSC amplitude, we incorporated paired pulse ratio (PPR) measurements in 
our experimental design.  Alterations in PPR are classically interpreted as suggestive of a 
change in presynaptic function.  As seen in figure 13a, 5 min application of LY354740 
caused a marginal increase in PPR.  A more robust and persistent increase in PPR was 
seen with the longer application of LY354740 (Figure 13b).  Interestingly, the 
enhancement of group II mGluR mediated effects on PPR mirrored that of the inhibition 
of the EPSCs.  Activation of group III mGluRs by L-AP4 also led to a long lasting 
increase in PPR that mirrored the inhibition of the EPSCs (Figure 13c).  As shown in 
Figure 13, both LY354740 and L-AP4 significantly increase PPR. 
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Figure 13.  Group II or III mGluRs function has a presynaptic locus  
a.  Time course of PPR from cells in which LY354740 was applied over 5 minutes (n=6).  
Insets are representative traces from time points indicated for a-c.  b.  Time course of 
PPR from cells in which LY354740 was applied over 15 minutes (n=9).  c.  Time course 
of PPR from cells in which 1 mM L-AP4 was applied (n=6).  d.  Graph of PPR at the 
initial peak depression of the EPSC.  Arrow indicates time at which analysis was 
performed.  Scales indicate 100 pA and 20 ms. 
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Discussion 
 
 The BNST, and in particular glutamatergic transmission within the BNST is 
believed to be a critical substrate for stress/anxiety pathways.  Metabotropic glutamate 
receptor ligands, in particular group II and group III mGluR agonists, produce anxiolytic 
effects on animal behavior in a variety of tasks (Fitzjohn et al., 1998; Klodzinska et al., 
1999; Pilc et al., 2002; Wieronska et al., 2004), however to date, the sites of actions 
responsible for these effects are unknown.  In this study, we report that fast glutamatergic 
transmission in the BNST of adult mice is depressed by these ligands. 
 Consistent with the function of group II mGluRs in other brain regions (Bushell et 
al., 1996; Macek et al., 1996; Kilbride et al., 1998), we find selective activation of group 
II mGluRs in the BNST can produce a reversible depression of synaptic transmission.  
We find that two group II mGluR selective agonists, DCG-IV and LY354740 (Fitzjohn et 
al., 1998), both inhibited glutamate-dependent field potentials and EPSCs, and that this 
effect was blocked by LY341495 at concentrations selective for group II mGluRs.  The 
effect of LY354740 on EPSCs is potent and concentration dependent, with maximal 
depression elicited by 100 nM LY354740.   Because DCG-IV has agonist activity at the 
NMDA receptor at higher concentrations (Uyama et al., 1997), we performed 
experiments with this compound in the presence of the NMDA receptor antagonist DL-
AP5.   
For the study of group III mGluRs we also used two agonists, L-AP4 and DCPG.  
L-AP4, the most commonly used selective group III agonist has a high affinity for 
mGluR4/6/8 and a low affinity for mGluR7 (Cartmell and Schoepp, 2000).  DCPG, a 
more recently described group III mGluR agonist, is a relatively specific mGluR8 agonist 
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(Linden et al., 2003).   The dose-response relationship for L-AP4 suggests the 
involvement of mGluR7, since high concentrations of L-AP4 did not produce saturating 
actions.  Consistent with this idea, anatomical evidence points to the expression of 
mGluR7, with weaker, if any, expression of mGluR4 in dBNST (Kinzie et al., 1995; 
Ohishi et al., 1995; Kinoshita et al., 1998).  However, significant effects were observed 
with low concentrations of L-AP4, suggesting the possible involvement of other group III 
mGluRs.  Consistent with this, we find that the mGluR8 agonist DCPG also decreases 
excitatory transmission.  At present it is unclear where mGluR8 is localized within 
BNST. 
 
Group II MGluRs Modulate Excitatory Transmission in the dBNST 
 
 Group II mGluRs are located primarily presynaptically and function to modulate 
transmitter release (Gereau and Conn, 1994; Shigemoto et al., 1996; Lujan et al., 1997; 
Anwyl, 1999), although there is also evidence for the function of group II mGluRs 
postsynaptically (Otani et al., 2002).  Group II mGluRs can couple to a variety of effector 
systems (Gereau and Conn, 1994), including regulation of cAMP production, direct  
modulation of ion channels, and in some cases activation of PLC and PLD (Otani et al., 
2002).  Consistent with immunohistochemical evidence of the presence of mGluR2 and 
mGluR3 in the BNST (Kinoshita et al., 1998; Tamaru et al., 2001), our data suggests 
group II mGluRs function to decrease excitatory transmission in this region.  The 
depression of glutamatergic transmission by group II mGluR agonists that we observed 
was accompanied by marked alterations in PPR, suggesting that the actions of the group 
II mGluRs in this case is likely a presynaptic one.   
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Interestingly, we found that while brief application of the group II agonists 
produced a reversible depression of glutamatergic transmission, more prolonged 
activation of the receptors produced a persistent, likely presynaptically mediated, 
depression of synaptic transmission in the BNST.  This persistent depression does not 
appear to be due to poor pharmacokinetics or a constitutively activated group II mGluR 
since late application of the antagonist LY341495 did not reverse the depressed EPSC. 
Long-term depression of excitatory transmission (LTD) induced by activation of 
group II mGluRs has been reported in a number of brain regions.  For example, group II 
mGluR-dependent LTD has been demonstrated in the BLA (Man et al., 2000), the 
nucleus accumbens (Robbe et al., 2002), the striatum (Kahn et al., 2001) and the mossy 
fiber-CA3 synapse (Kobayashi et al., 1996).  In these regions, evidence suggests that the 
persistent depression is mediated presynaptically via a reduction in glutamate release.  In 
contrast, thalamic inputs to the lateral nucleus of the amygdala (Heinbockel and Pape, 
2000), as well as glutamatergic synapses in the dentate gyrus and medial prefrontal cortex 
(Otani et al., 2002; Kawasaki et al., 2004) undergo a group II mGluR-mediated LTD  that 
appears to be postsynaptically elicited.  The LTD that we observe in the BNST is 
associated with a persistent alteration in paired-pulse ratios, suggesting that it may be 
mediated by presynaptic alterations in glutamate release.  In contrast to group I mGluR 
LTD in the hippocampus (Doherty et al., 1997), yet similar to group II LTD in the 
striatum (Kahn et al., 2001), LTD in the BNST was not caused by slow washout of 
LY354740 or a constitutively activated receptor because application of the group II 
antagonist LY341495 during the washing period did not affect the magnitude of LTD. 
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Group III MGluRs Modulate Excitatory Transmission in the dBNST  
 
In addition to the effects of group II mGluR activation, the group III agonist L-
AP4 clearly inhibited the synaptically-evoked responses of BNST neurons. Like group II 
mGluRs, group III mGluRs are coupled to a variety of effectors, including inhibition of 
cAMP production, and direct modulation of ion channels (Gereau and Conn, 1994).   
As with the group II mGluR activation, we find that activation of group III 
mGluRs can elicit a lasting, presynaptically mediated depression of EPSCs in the BNST, 
suggesting that activation of group III mGluRs may also produce LTD in this region.  
Indeed, LTD requiring group III mGluRs has been observed at glutamatergic inputs on 
interneurons in CA3 (Laezza et al., 1999).  Unfortunately however, at present we cannot 
rule out the possibility that the persistent depression is a consequence of poor drug 
washout since antagonist development for group III mGluRs has lagged behind the other 
groups. 
 
Group II MGluR Activation Fails to Enhance Inhibitory Effects of Group III MGluR 
Activation 
 
 Multiple mGluRs with different signaling cascades have been shown to function 
at the same synapses(Kawasaki et al., 1998).  We find that activation of group II or group 
III mGluRs does not completely block excitatory transmission in the BNST.  We 
therefore hypothesized that either 1) the receptors function at differing afferent pathways, 
or 2) there was incomplete modulation of glutamatergic transmission by activation of 
mGluRs at each synapse.  In order to begin to test if group II and group III mGluRs act 
on different inputs or different signaling pathways we co-applied specific agonists.  
Activation of group II mGluRs did not enhance the inhibition induced by the group III 
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agonist.  This suggests the interesting possibilities that either these mGluRs function at a 
common pool of afferent inputs, and/or that they converge to some degree on common 
effector pathways.  Future higher resolution anatomical studies combined with more 
mechanistic studies will be necessary to address these possibilities. 
 
 
Behavioral Relevance 
 
 The present findings are consistent with the anxiolytic properties of agonists of 
group II and group III receptors.  AMPA receptor antagonists directly injected into the 
BNST reduce potentiated startle responses (Walker and Davis, 1997), suggesting that 
dampening fast glutamatergic signaling in the BNST can produce anxiolytic responses.  
Thus the depression of this transmission produced by group II and group III mGluR 
agonists that we observe in the present study would be predicted to have similar 
outcomes on behavior.  Reduced glutamatergic drive within the BNST would likely 
decrease output to the stress and reward circuitry, potentially reducing recruitment of the 
HPA axis. 
 
Conclusions 
 
The BNST plays a critical role in the response to stress and anxiety through a 
mechanism that involves excitatory glutamatergic transmission.  The present study has 
demonstrated that excitatory transmission in the BNST is modulated by activation of 
group II and III mGluRs.  Thus mGluRs within the BNST represent a candidate 
therapeutic target for the treatment of anxiety disorders.  Behavioral studies will be 
necessary to test this possibility.   
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CHAPTER IV 
 
ERK1-DEPENDENT MGLUR5-INDUCED LTD IN THE BED NUCLEUS OF 
THE STRIA TERMINALIS IS DISRUPTED BY COCAINE SELF-
ADMINISTRATION. 
 
Introduction 
 A major function of group I mGluR activation is to produce a persistent 
weakening of glutamatergic transmission at synapses in the CNS.  There appear to be at 
least two major mechanisms through which this is accomplished.  One involves the 
recruitment of endocannabinoid signaling and presynaptic alterations, and has been 
observed in the dorsal and ventral striatum (Gerdeman and Lovinger, 2001; Sung et al., 
2001; Robbe et al., 2002).  A second major mechanism is through endocannabinoid-
independent signaling mechanisms (Rouach and Nicoll, 2003), and has been extensively 
characterized in the hippocampus.  Both presynaptic (Gereau and Conn, 1995; Watabe et 
al., 2002; Zakharenko et al., 2002) and postsynaptic mechanisms (Huber et al., 2000; 
Huber et al., 2001; Snyder et al., 2001; Nosyreva and Huber, 2005)  have been described 
for endocannabinoid-independent forms of group I mGluR LTD.   
 Endocannabinoid-dependent group I mGluR-induced LTD is disrupted in the 
ventral striatum in animals previously exposed to cocaine, suggesting that alterations in 
this form of plasticity may play a role in cocaine-induced alterations in animal behavior 
(Swanson et al., 2001).  To date, however, the role of endocannabinoid-independent 
group I mGluR LTD has not been explored.  We have addressed this question by 
examining effects of activation of group I mGluRs at excitatory synapses within the bed 
nucleus of the stria terminalis (BNST), a region critical in mediating stress-reward 
 81
interactions (Delfs et al., 2000; Stewart, 2000).  We find that activation of group I 
mGluRs produces two distinct effects.  First, a combined mGluR1 and mGluR5 
activation induced a transient depression that is cannabinoid 1 receptor (CB1R) 
dependent. Second, as with endocannabinoid-independent group I mGluR LTD in the 
adult hippocampus, we find that activation of mGluR5 induces an ERK-dependent LTD.  
Surprisingly, our data demonstrate that this LTD requires the ERK1 rather than ERK2 
isoform, establishing a key role for this isoform in the CNS.  Finally, we find that this 
LTD is dramatically reduced following cocaine self-administration, suggesting a role for 
this form of plasticity in the actions of psychostimulants on anxiety and reward circuitries 
and their emergent control of animal behavior. 
 
Results 
 
Group I MGluRs Depress Excitatory Transmission in the BNST 
 To study the effects of group I mGluR activation on excitatory synaptic 
transmission in the BNST, we used local afferent stimulation and both extracellular and 
whole-cell patch clamp recording of postsynaptic responses as previously described; 
(Weitlauf et al., 2004; Egli et al., 2005; Grueter and Winder, 2005).  To activate group I 
mGluRs, the specific agonist (RS)-3,5-Dihydroxyphenylglycine (DHPG) was briefly bath 
applied.  Under extracellular recording conditions, following 15 min superfusion of 
DHPG (100µM), the amplitude of the N2 (synaptic, glutamatergic component) decreased 
to 79±4 % of baseline.  The N2 amplitude 40 minutes following DHPG remained 
depressed at 86±2 % of baseline (Figure 14; p<0.05).  These effects were independent of 
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changes in the N1, the nonsynaptic, predominantly axonally-mediated response, 
indicating that depression of the synaptically-evoked response occurs independent of 
gross alteration of the number of axons recruited by the local afferent stimulation. 
 DHPG also reduced excitatory postsynaptic currents (EPSCs) in a concentration-
dependent manner (Figure 14).  100µM DHPG reduced EPSCs to 52±5% of baseline at 
the peak effect that remained depressed (62±6% of baseline) 30 minutes post-DHPG 
application (Figure 14).  The DHPG-induced LTD of EPSCs was independent of NMDA 
receptor function as robust LTD was elicited in slices pretreated with the NMDA receptor 
antagonist, DL-AP5 (100µM, peak effect: 46±11% of baseline, 30 min. post-DHPG: 
65±8% of baseline; Figure 14).  
 To begin to identify the group I mGluR subtype, mGluR1 and/or mGluR5, 
involved in the DHPG-induced depression of EPSCs we applied DHPG in the presence 
of selective mGluR1 and mGluR5-specific antagonists.  In the presence of the mGluR5-
specific antagonist, MPEP (10µM), the initial component of the depression was not 
significantly altered (69±8% vs. 52±5% of baseline), however, 30 minutes post-DHPG, 
the depression was significantly attenuated (94±3% vs. 62±6% of baseline, p<0.05; 
Figure 15).  While application of MPEP alone produced no effect on basal transmission, 
application of MPEP in combination with the mGluR1 selective antagonist LY367385 
(100 µM), produced a slight ~10% depression of the EPSC (data not shown).  When 
DHPG was then applied in the presence of both of these antagonists, both the initial 
DHPG-induced depression (74±8% vs. 52±6% of baseline, Figure 15, p<0.05) and the  
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Figure 14. Group 1 mGluR activation in the BNST results in LTD of excitatory 
transmission.   
(A)  Diagram of coronal mouse brain containing the BNST.  (B)  Application of DHPG-
induced persistent reduction in the synaptic response (N2), as measured by the peak 
amplitude of field potential responses, normalized to the average value during the basal 
period prior to drug application.  Inset:  Sample traces from one experiment before 
(heavy line) and after (light line) DHPG application, average of 6 consecutive traces at 
18-20 and 38-40 min.  Error bars, SEM.  (C)  Timecourse of DHPG-induced reduction in 
EPSC amplitude, normalized to the average value during the basal period prior to drug 
application.  Inset:  Representative EPSC traces from BNST neurons pre and post DHPG 
application, average of 10 consecutive traces from min 4-5 and min 12-13.  (D) 
Concentration-response curve of peak DHPG-induced depression of EPSCs (n=3-12).  
 
 
 84
  
 
 
Figure 15. Pharmacological antagonists show DHPG induces a dual component 
in the BNST, the late component being mGluR5 dependent.   
(A)  The NMDA receptor antagonist, DL-APV (100 μM) does not alter DHPG induced 
depression of EPSCs (n=3).  (B)  MPEP blocks the late but not the peak effect fo DHPG 
on EPSCs (n=3).  (C)  Both the mGluR1 antagonist LY 367385 (100μM) and MPEP (10 
µM) are required to attenuated the peak DHPG effect on EPSCs (n=3).  D.  MPEP does 
not reverse DHPG-induced LTD (n=3). 
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persistent depression (89±7% vs. 62±6% of baseline, p<0.05) were significantly 
attenuated compared to DHPG alone.  Thus, these data suggest that DHPG-induced 
persistent depression of excitatory transmission in the BNST requires mGluR5 activation, 
and that mGluR1 activity is additionally required for the early component.  
 To verify that DHPG-induced persistent depression was not simply the result of 
poor washout of DHPG, or perhaps of induction of constitutive activity of group I 
mGluRs, we again applied MPEP, this time 20 minutes after washout of DHPG (Figure 
15).  At this time point, MPEP failed to alter EPSC amplitude, suggesting that transient 
activation of mGluR5 induces LTD. 
 
Postsynaptic Induction of MGluR5-Dependent LTD in BNST 
 In the hippocampus, mGluR5-dependent LTD is thought to be induced 
postsynaptically (Watabe et al., 2002).  To begin to determine the site of induction of 
mGluR5-dependent LTD in the BNST, we replaced GTP with 1 mM guanosine-5'-O-(2-
thiodiphosphate) (GDP S) in our standard potassium gluconate-based electrode-filling 
solution to inhibit activation of postsynaptic G proteins.  Dialyzing GDP S into the 
postsynaptic cell blocked DHPG-induced LTD (114±20% of baseline) in the BNST while 
having no effect on the early component (66±8% of baseline; Figure 16).  In contrast, we 
tested the effects of GDPβS in the postsynaptic cell on depression of synaptic 
transmission induced by activation of group 2 mGluRs.  In the BNST, group II mGluR 
activation produces LTD at excitatory synapses that likely results from a presynaptic 
action (Grueter and Winder, 2005).  Inclusion of GDPβS in the pipette did not alter the 
ability  
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Figure 16. Postsynaptic G-proteins mediated the DHPG-induced LTD while no 
changes in probability of release or synaptic cleft glutamate concentrations are 
detected. 
(A)  Upper panel:  Representative experiment showing blockade of DHPG-induced LTD 
but not LY354740-induced LTD by intracellular GDPβS (1mM).  Lower Panel:  Access 
resistance is unaltered in the presence of GDPβS during the duration of the experiment.  
(B)  Blockade of postsynaptic GPCR-signaling with GDPβS prevents DHPG-induced 
depression of EPSCs (closed squares, n=5) but not control cells containing GTP (open 
circles).  (C)  Chelation of postsynaptic Ca2+ with 20mM BAPTA in the intracellular 
solution does not alter DHPG-induced depression of EPSCs (n=6).  (D)  Timecourse of 
normalized PPR illustrating transient increase in release probability in response to DHPG 
(left axis).  As illustrated, DHPG causes a transient increase in PPR during the peak 
effect on EPSC amplitude but returns to basal levels during the LTD (closed squares, 
PPR; open circles EPSC amplitude).  (E)  Percent inhibition of EPSCs by γDGG is 
unchanged before and after DHPG application (n=5).   
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of the group II mGluR agonist LY 354740 (1μM) to reduce synaptic transmission (Figure 
16). Further, GDPβS did not alter basal transmission in time-matched recordings 
(data not shown).  These results indicate a postsynaptic G-protein is necessary for 
induction of LTD though it does not rule out the possibility of presynaptic maintenance 
of this LTD. 
  Results in the literature are mixed as to whether postsynaptic calcium rises are 
required for mGluR5-dependent LTD (Bolshakov and Siegelbaum, 1994; Oliet et al., 
1997; Maejima et al., 2001; Rae and Irving, 2004).  To begin to test for postsynaptic 
calcium dependency, we added 20 mM BAPTA to our standard potassium gluconate-
based electrode-filling solution to chelate intracellular calcium.  Introduction of 20 mM 
BAPTA to the postsynaptic cell had no significant effect on DHPG LTD (66±8% of 
baseline, Figure 16).   
 
Synaptic Locus of Group I MGluR-Mediated Effects 
 To begin to assess the synaptic mechanisms involved in DHPG-induced 
depression of transmission, we examined the effects of DHPG application on the ratio of 
EPSC amplitudes in response to closely spaced (50 ms) paired stimuli (paired-pulse ratio, 
PPR) to query whether DHPG produces alterations in presynaptic release probability.  
During the initial, peak depression of the EPSC produced by DHPG, we found a 
significant increase in the PPR (120±6%, p<0.05, Figure 16). However, there was no 
significant change in PPR during DHPG LTD (104±5%, p=0.37, Figure 16).  In 
comparison, activation of either group 2 or group 3 mGluRs, which commonly function 
presynaptically as autoreceptors, caused a persistent increase in PPR in the BNST 
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(Grueter and Winder, 2005).  These data suggest that while the transient peak effect of 
DHPG involves an alteration in release probability, the LTD does not.   
While the PPR data suggest that alterations in release probability cannot account 
for the LTD induced by DHPG, presynaptic mechanisms that altered either vesicular 
glutamate concentration, fusion pore release dynamics, or synaptic glutamate buffering 
could still account for DHPG-induced LTD.  To begin to address these possibilities, we 
performed experiments comparing the effects of bath application of a low affinity AMPA 
receptor antagonist, γDGG (Chen and Diamond, 2002), before and after DHPG 
application (Figure 15E).   Alterations in synaptic cleft glutamate concentration by 
DHPG would be predicted to alter the antagonism of the EPSC by γDGG.  We found that 
brief application of 500µM γDGG produced an ~50% inhibition of the EPSC, which 
nearly completely reversed upon washout.  The percent inhibition by this application was 
unchanged when γDGG was again applied 30 minutes after DHPG application (Figure 
16E).  These data suggest that DHPG-induced LTD is not likely due to alterations in 
glutamate concentrations at the synaptic cleft. 
 Spontaneous, CNQX-sensitive (data not shown) miniature excitatory postsynaptic 
currents (mEPSCs) were also analyzed in the BNST following DHPG application to 
further assess mechanisms by which transmission is modulated.  Representative traces of 
mEPSCs measured at -90 mV before and after DHPG application are shown in Figure 17.    
Application of 100µM DHPG significantly decreased frequency of mEPSCs both at the 
transient time point (68.6±6% of baseline, p<0.05, Figure 17) and at the late time point 
(64.4±9% of baseline, p<0.05, Figure 17).  However, there was no significant effect on 
mEPSC amplitude at either the transient time point (96.8±5% of baseline, p>0.05,  
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 Figure 17.   DHPG decreased the frequency but not amplitude of BNST mEPSCs.   
(A)  Sample current traces of mEPSCs in a BNST neuron before DHPG application (basal) and at 30 min 
post (late) DHPG.  (C) Cumulative probability plot of DHPG induced effects on mEPSC inter-event 
interval within the basal (3-5 min, open squares) and late (min 35-37 closed circles) time periods.  (n=7; 
p<0.05 K-S test).  (D)  Cumulative probability of effects of DHPG on mEPSC amplitude within the same 
current recordings as shown in C.  Inset, representative traces before DHPG application and during DHPG 
mediated LTD. (E, F)  Percent of mean effect of DHPG on mEPSCs frequency (E), and amplitude (F) 
during the peak and 30 minutes post (late) DHPG (*p<0.05).   
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Figure 17) or the late time point (97.6±7% of baseline, p>0.05, Figure 17).  Additionally, 
no gross changes in the kinetics of mEPSCs were observed after DHPG application 
(inset, Figure 17), however, a small but significant change in decay time (tau) was 
observed (2.38±0.39ms basal vs. 2.68±0.51ms 30 min post DHPG; n=7, p<0.05).    
 
DHPG-Induced Transient Effects, but not LTD, are Reduced in CB1R Knockout Mice 
 
  Group I mGluR-induced LTD has been demonstrated to be presynaptically 
maintained and dependent on endocannabinoid receptor CB1 (CB1R) signaling in the 
nucleus accumbens and  striatum (Maejima et al., 2001; Robbe et al., 2003) while being 
independent of cannabinoid signaling in the hippocampus (Rouach and Nicoll, 2003).  To 
test whether the CB1R is involved in effects of DHPG on EPSCs in BNST, we examined 
the effects of DHPG (100 µM) on EPSCs recorded from BNST neurons in slices obtained 
from CB1R knockout mice (Zimmer et al., 1999).  Interestingly, the initial depression of 
the EPSC by DHPG was significantly blunted in neurons from CB1R knockout mice 
(84±5% of baseline, p<0.05) compared to control animals at the same time point (Figure 
18).  Consistent with these data, we found that in contrast to results obtained in wildtype 
mice, PPR following DHPG application was unaltered in these experiments (108±6% of 
baseline, p>0.05, Figure 18).  The CB1R knockout mice did not have a generalized 
deficit in receptor regulation of presynaptic function, however, as activation of group II 
mGluRs in the BNST of CB1R knockout mice resulted in an increase in PPR (154±4% of 
baseline, data not shown) as previously described in wildtype mice (Grueter and Winder, 
2005). 
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 While the acute effect of DHPG on EPSCs was blunted in the CB1R knockout 
mice, DHPG-induced LTD was still robustly elicited in these animals (73±7% vs. 62±6% 
of baseline 30 minutes after DHPG administration, Figure 18).  These data suggest that 
the initial component of the DHPG-induced depression of the EPSC, as in the 
hippocampus, is mediated through the CB1R, while the mGluR5-mediated LTD in the 
BNST is independent of CB1R signaling. 
 
 
DHPG-Induced Depression of Synaptic Transmission in the BNST is ERK1 Dependent 
 
 CB1R-independent group I mGluR-dependent LTD in the hippocampus has been 
reported to require ERK activation (Gallagher et al., 2004).  Further, group I mGluRs 
recruit ERK activity in a variety of contexts (Mao and Wang, 2003; Mao et al., 2005).  In 
order to examine the role of ERK in DHPG-induced depression of EPSCs in the BNST 
we utilized two converging approaches.  First, we applied DHPG (100 µM) in the 
presence of the MEK inhibitor (U0126, 20µM) to BNST slices while recording EPSCs.  
The presence of the MEK inhibitor significantly attenuated, but did not ablate, the early 
component of the DHPG-mediated depression of transmission to 69±5% vs. 52±5% of 
baseline (Figure 19).  However, the DHPG-induced LTD was abolished in the presence 
of the MEK inhibitor (92±10% of baseline, 30 min post DHPG, Figure 19).   
We next examined the effects of DHPG on EPSCs in the BNST of ERK1 
knockout mice.  Similar to the U0126 experiments, application of DHPG in the BNST of 
ERK1 knockout mice produced an initial depression of the EPSC that was significantly 
attenuated, though still present (74±4% of baseline).  Surprisingly, however, LTD was  
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Figure 18. The peak component of the EPSC is CB1 receptor dependent but the 
LTD is CB1 R independent.   
(A)  Summary of the effects of DHPG (100 µM) on EPSCs in BNST from CB1 receptor 
null mice (black squares; n=9) and control animals (gray circles; n=12).   (B)  The PPR is 
unchanged in the CB1R null BNST following DHPG application.  (C)  Bar graph 
representing the basal, peak and late effects of DHPG on PPR in control and CB1R null 
mice (n=9 and 12, respectively; * p<0.05 compared to basal). 
 
 94
  95
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. mGluR5-induced LTD in the BNST is ERK dependent. 
 (A)  DHPG induced LTD of EPSCs is abolished by the presence of the MEK inhibitor, 
U0126 (20 µM, n=6).  (B)  EPSCs from BNST neurons from ERK1 null mice do not 
elicit LTD following DHPG application (n=6).  Inset represents presence/absence of 
ERK1 in control and ERK1 (-/-) mice.  (C)  Representative slice illustrating size and 
location of BNST and striatal punches taken for biochemical analysis.  (D)  
Representative immunoblot for phosphorylated ERK1/ERK 2 and pan ERK1/ERK2 from 
either the BNST or the striatum in the absence or presence of DHPG.  (E and F)  
Quantitative analysis of ERK1 and ERK2 phosphorylation in the BNST (E; n=8; 
*p<0.05) and the striatum (F, n=8; *p<0.05). 
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completely ablated (102±7% of baseline, Figure 19).  The effects of DHPG on EPSCs in 
the BNST from wild-type littermates were not different from C57Bl6j mice (Figure 19).   
 
DHPG Activates ERK in BNST 
 The above results suggest that ERK1 activity is required for DHPG-induced LTD.  
Since group I mGluR activation has been shown to activate ERK1/2 in other brain 
regions (Choe and Wang, 2001; Adwanikar et al., 2004; Gallagher et al., 2004), we tested 
whether DHPG application activated ERK1 and ERK2 in the dorsal BNST.  Frozen tissue 
punches from the BNST and striatum were obtained following a 5 min exposure to 
DHPG (100μM) (Figure 19).   
First, as has been previously reported, we found that DHPG produced robust 
activation of ERK in striatum (Choe and Wang, 2001); Figure 19).  Striatal ERK2 
phosphorylation was increased almost two fold in response to DHPG (185±4% of basal, 
p<0.05, Figure 19) while ERK1 phosphorylation was not significantly altered (75±3% of 
basal, p>0.05, Figure 19).  Thus, as is the case in many brain regions, ERK2 appears to 
be the predominant isoform activated by group I mGluRs in the striatum.  Interestingly, 
in the BNST, the relative ratio of ERK1 to ERK2 expression was higher than in striatum 
(Figure 19).  Moreover, we observed a relatively robust increase in ERK1 
phosphorylation in the BNST in the presence of 100 μM DHPG (137±9% of basal, 
p<0.05, Figure 19).  DHPG treatment caused only a very small increase in ERK2 
activation (111±4% of basal, p<0.05, Figure 19).  These data suggest activation of group 
I mGluRs results in ERK1 and to a lesser extent ERK2 activation in the BNST.   
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MGluR5-Dependent LTD in the BNST is Greatly Attenuated by Contingent in vivo 
Cocaine Administration 
 
 Intraperitoneal cocaine administration disrupts endocannabinoid dependent, group 
I mGluR-induced LTD in the nucleus accumbens (Swanson et al., 2001; Fourgeaud et al., 
2004), and activates ERK in the BNST (Valjent et al., 2004).  Thus we examined the 
effects of self-administration of cocaine on mGluR5-dependent LTD in the BNST.  After 
food training, mice were allowed 3 hour daily sessions of access to either cocaine or 
saline on a fixed ratio 1 (FR1) schedule.  Animals in the cocaine group lever pressed 
significantly more than saline controls (Figure 20).  Twenty four hours after the last day 
of self-administration (10 days total), the mice were sacrificed, and brain slices prepared 
for electrophysiological analysis.  In studies in which the experimenter was blinded to the 
conditions, the initial component did not differ in slices prepared from the DHPG-
induced depression for cocaine self-administering (51±6% of baseline, Figure 20) and 
saline administering (61±4% of baseline, Figure 20) mice. However, the persistent 
depression of EPSCs by DHPG was significantly attenuated in slices prepared from 
cocaine self-administering mice (83±9% of baseline, when compared to saline control 
animals, 63±5% of baseline, p<0.05).  The cumulative probability of DHPG-induced 
LTD is also significantly altered in cocaine vs. saline treated mice (Figure 20; KS-Test, 
D=0.57 with a p<0.05).  Operant training did not alter DHPG-induced LTD as there is no 
difference between animals self-administering saline and naïve animals, 61±4% vs. 
62±6%, respectively.  PPR from cocaine treated and saline treated groups were not 
different than naïve animals (data not shown). 
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Figure 20.  MGluR5-dependent LTD is attenuated by contingent in vivo cocaine.  
(A)  Summary of active lever presses for cocaine/saline (*p<0.05).  B.  Summary of the 
effects of cocaine self-administration on mGLuR5-induced LTD in the BNST (cocaine, 
n=9; saline, n=13).  C.  Cumulative probability of DHPG induced depression of 
excitatory transmission from saline administered (dotted line) and cocaine administered 
(solid line) mice. 
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Discussion 
Group I mGluRs are necessary for many of the behavioral alterations produced by 
cocaine administration (Chiamulera et al., 2001; McGeehan and Olive, 2003; Herzig and 
Schmidt, 2004; Kenny et al., 2005; Lee et al., 2005).  Several studies indicate that 
signaling by mGluR5 in the nucleus accumbens is altered by cocaine administration 
(Swanson and Kalivas, 2000; Swanson et al., 2001). The BNST is a brain region uniquely 
positioned to modulate the integration of motivational and higher order processive 
innervations, receiving input from limbic regions such as the amygdala and hippocampus, 
and projecting to areas involved in the reward/motivation and stress circuitry, the VTA, 
NAc and PVN (Herman and Cullinan, 1997; McDonald et al., 1999; Georges and Aston-
Jones, 2002). Thus in the present studies, we have examined group I mGluR regulation of 
excitatory transmission in the BNST.  
The data presented in the present work demonstrates that activation of group I 
mGluRs in the BNST leads to a postsynaptically-induced persistent weakening of 
excitatory transmission.  This depression occurs through two temporally distinct 
mechanisms as detailed below.  Moreover, we define a novel role for the ERK1 MAP 
kinase isoform, which has to this point received little attention in neuronal function.    
Finally, both group I mGluRs and ERK have been shown to play important roles in the 
behavioral actions of psychostimulants.  Consistent with this, we find that the DHPG-
induced LTD in the BNST is disrupted following cocaine self administration. 
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Group I MGluR Activation Depresses Excitatory Transmission in the BNST via 
Temporally Distinct Phenomena 
 
We find that activation of group I mGluRs in the BNST results in two temporally 
and mechanistically distinct effects on excitatory synaptic transmission (Figure 21).  
DHPG-induced acute depression differs from the persistent depression in a number of 
respects.  Using mGluR-subtype specific antagonists, we present data suggesting that the 
persistent depression is induced primarily by mGluR5 activation, while mGluR1 
activation is additionally required for the acute depression induced by DHPG application. 
This differentiation between the role of mGluR1 in the acute depression and mGluR5 in 
the LTD is consistent with the distinct action of these group I mGluR subtypes in the 
hippocampus on LTD and excitability of hippocampal neurons (Mannaioni et al., 2001; 
Faas et al., 2002).  We used multiple pharmacological, genetic and biophysical tools to 
further differentiate these processes, as discussed below.   
 
CB1R is Required for the Acute Presynaptic Phase of DHPG-Induced LTD 
 
In contrast to the persistent depression described in detail below, the acute 
depression is associated with a robust increase in PPR of evoked EPSCs and a decrease in 
mEPSC frequency, suggesting that it involves a decrease in release probability.  At many 
CNS synapses, presynaptic actions of group I mGluRs are mediated by the 
endocannabinoid system (Maejima et al., 2001).  Similar to findings in the hippocampus 
(Rouach and Nicoll, 2003) and NAc (Robbe et al., 2002), we found that the initial phase 
of the DHPG-mediated depression is ablated in CB1R knockout mice. These data suggest 
that the acute depression is mediated by mGluR1/5-dependent production of 
endocannabinoids which then act on presynaptic CB1 receptors to depress transmission.   
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Figrue 21.   Model illustrating group I mGluR activation at excitatory BNST 
synapses.  Left:  Endocannabinoids act presynaptically to inhibit probability of release 
following mGluR1/5 activation.    Right:  A postsynaptic G-protein regulates 
ERK1/mGluR5-dependent LTD in the BNST resulting in a silencing of synapses. 
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As seen with DHPG-induced acute depression in cerebellar Purkinje cells 
(Maejima et al., 2001), the mGluR-mediated early CB1 receptor-dependent signaling 
may be through a Ca2+ independent pathway as the presence of 20mM BAPTA in the 
postsynaptic cell did not alter DHPG induced depression of excitatory transmission or 
PPR.  An endocannabinoid candidate, 2-arachidonoylglycerol (2-AG), is thought to be 
produced downstream of PLC activity in a largely calcium-independent manner.  
Another, endocannabinoid candidate, anandamide, appears to be more calcium dependent 
(Maejima et al., 2001; Varma et al., 2001; Freund et al., 2003; Hashimotodani et al., 
2005).  Thus, one possibility is that the CB1R-dependent component of DHPG-induced 
depression that we observe is mediated through the generation of 2-AG.  However, it is 
important to note that we cannot exclude the possibility that endocannabinoids generated 
by neighboring cells in a Ca2+-dependent manner contribute to these effects.   
  
The Late, Persistent Phase of the MGluR5-Dependent LTD is Postsynaptically Induced
In addition to the acute effects of group I mGluR activation, we find that a persistent 
depression is elicited through independent mechanisms.  As mentioned above, 
pharmacological evidence suggests the late phase of the DHPG-induced LTD is mGluR5 
dependent as well as CB1R independent.  The site of action of DHPG to produce the 
persistent depression of transmission is a bit more elusive.  The induction of LTD appears 
to have a postsynaptic component, as dialysis of the postsynaptic cell with GDPβS 
blocked DHPG-induced LTD.  The LTD was not associated with alterations in PPR, 
consistent with the lack of CB1R dependence, suggesting the maintenance of this LTD is 
not through an alteration of release probability.  It is possible that the DHPG-induced 
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LTD is due to alterations in glutamate concentrations at the synapse (i.e., changes in 
vesicular loading or reuptake of glutamate).  To test this possibility assessed the 
effectiveness of the low-affinity AMPAR antagonist γDGG before and 30 min after 
DHPG application.  If synaptic cleft concentrations of glutamate were reduced following 
DHPG-induced LTD we would expect an increase in the γDGG mediated depression of 
excitatory transmission (Chen and Diamond, 2002).  As this was not the case we 
conclude that vesicular content and/or reuptake of glutamate are not altered during 
DHPG-induced LTD.    
Similar to what is seen in the hippocampus (Snyder et al., 2001), analysis of 
mEPSCs after DHPG treatment revealed a persistent decrease in the mEPSC frequency 
but not amplitude.  As this mEPSC frequency decrease was not associated with an 
alteration in PPR in the evoked EPSCs, we interpret these data to suggest that DHPG-
induced LTD is due to a reduction in n (number of available synaptic sites) rather than p 
(release probability).  Such a “silencing” of synapses could occur through either pre- or 
postsynaptic actions, or a combination of the two.  This idea is consistent with trafficking 
of AMPA receptors from the synapse following DHPG application as was shown in the 
hippocampus (Snyder et al., 2001; Xiao et al., 2001; Mangiavacchi and Wolf, 2004; 
Nosyreva and Huber, 2005). 
 
A Novel Role for ERK1 in MGluR5-LTD 
The MAPK/ERK signaling cascade plays a crucial role in a variety of cell 
regulatory events.  Much emphasis has been placed on the role of this signaling cascade 
in learning and memory, and in glutamatergic synaptic plasticity at a variety of synapses  
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(Adams and Sweatt, 2002; Sweatt, 2004).  In particular, MEK inhibitors block the 
induction of several forms of NMDA-receptor dependent LTP and LTD throughout 
synapses of the hippocampus and the amygdala (for review see Sweatt, 2004).  A more 
recent, growing literature indicates that the ERK signaling cascade plays a critical role in 
behavioral alterations produced by psychostimulants.  Inhibitors of the ERK signaling 
cascade administered in vivo reduce psychostimulant mediated behavioral sensitization 
(Valjent et al., 2005).  It has also been suggested that ERK activation is involved in the 
incubation of cocaine craving in a region-specific manner (Lu et al., 2005).   Further, in 
vivo psychostimulant administration produces activation of ERK in the reward circuitry 
including, strong activation within the BNST (Valjent et al., 2000; Valjent et al., 2004).   
 To date, evidence has suggested that the primary ERK isoform involved in these 
processes is ERK2 (Sweatt, 2004).  First, ERK2 is the predominant isoform expressed in 
the hippocampus and amygdala.  Second, these forms of synaptic plasticity are either 
normal (Selcher et al., 2001) or only subtly altered (Mazzucchelli et al., 2002) in ERK1 
knockout mice.  Third, multiple labs have suggested that stimuli that promote these forms 
of synaptic plasticity may selectively activate ERK2 (Adams and Sweatt, 2002). 
Here, we provide evidence that ERK1 rather than ERK2 plays a critical role in 
mGluR5-induced LTD in the BNST.  By using an inhibitor (U0126) targeting the MEKs 
that activate ERK1/ERK2 we were able to show that the ERK signaling cascade is 
necessary for mGluR5-induced LTD in the BNST.  MEK inhibitors like U0126 do not 
allow for distinction of the relative roles of ERK1 and ERK2. Because ERK1 expression 
relative to ERK2 is stronger in the BNST than many other regions (Figure 18), we took 
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advantage of the availability of mice with a targeted deletion of ERK1.  As seen in Figure 
18, in ERK1 knockout mice, DHPG application in the BNST does not induce LTD.  
Further, consistent with a role specifically for ERK1 in DHPG-induced LTD in the 
BNST, we find that DHPG application preferentially activates ERK1 in the BNST, in 
contrast to the striatum, where ERK2 is the predominant isoform activated.   
At present, very little is known about the distinctive roles of the ERK1 and ERK2 
isoforms, as they are highly homologous (Chen et al., 2001).  However, several studies, 
primarily in non-neuronal systems, have identified proteins and/or drugs that produce or 
facilitate selective activation of ERK1 versus ERK2.  For example, MEK-binding partner 
1 (MP1) selectively facilitates ERK1 activation and binds with considerable selectivity to 
ERK1 over ERK2 (Schaeffer et al., 1998).  While little information exists for substrates 
differentially phosphorylated by ERK1 and ERK2, data from knockout mice point to 
differences in function.  For example, while ERK1 knockout mice are viable and fertile 
(Selcher et al., 2001; Pages and Pouyssegur, 2004), targeted disruption of ERK2 produces 
a lethal mutation (Adams and Sweatt, 2002).  Further, while much pharmacological 
evidence suggests that the MAP kinase signaling cascade plays an important role in 
NMDA receptor-dependent synaptic plasticity and learning and memory, hippocampal 
and amygdala based learning are unimpaired in ERK1 knockout mice (Selcher et al., 
2001), and NMDA receptor-dependent plasticity is either normal (Selcher et al., 2001), or 
altered in complex ways in ERK1 null mice (Mazzucchelli et al., 2002).   
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Group I MGluRs and Drug Addiction 
 Our results indicate that mGluR5 is responsible for the DHPG-induced LTD in 
the BNST.  As mentioned above, behavioral studies demonstrated that genetic deletion of 
mGluR5 as well as pharmacological blockade of mGluR5 resulted in reduced cocaine 
induced hyperactivity and reinforcing properties as well as reduced rewarding properties 
of cocaine (Chiamulera et al., 2001; Herzig and Schmidt, 2004; McGeehan et al., 2004; 
Lee et al., 2005). While the specific site of action of mGluR5 function in cocaine 
mediated behavioral and rewarding properties are still unknown, we show that, like in the 
NAc (Swanson et al., 2001; Fourgeaud et al., 2004), in vivo cocaine administration 
attenuates DHPG-induced LTD.  Therefore, alterations in mGluR5 function in the BNST 
may play a key role in behavioral properties of addiction. 
 
Excitatory Transmission and Drug Addiction 
Lasting changes in the efficacy of glutamatergic synaptic transmission in specific 
brain regions has been suggested to play an important role in the neuroadaptations that 
occur after substance abuse (Hyman and Malenka, 2001; Winder et al., 2002; Kalivas, 
2004; Wolf et al., 2004).  Recent work suggests both psychostimulants and stress induce 
LTP in the VTA and psychostimulants alter NAc synaptic plasticity (Swanson et al., 
2001; Thomas et al., 2001; Saal et al., 2003; Dong et al., 2004).  As the BNST projects to 
the VTA and NAc it is possible that the BNST plays a role in the integration of 
information leading to adaptive changes in synaptic responses following administration 
of drugs of abuse.  Indeed, this brain region plays a critical role in stress-induced 
reinstatement of drug seeking (Erb et al., 1996; Shaham et al., 2000), as well as morphine 
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withdrawal-induced conditioned place aversion (Aston-Jones et al., 1999).  Moreover, 
evidence suggests that this region, and in particular glutamatergic transmission within 
this region, plays a critical role in anxiety-like behavior in rodents (Walker et al., 2003).  
Thus persistent regulation of glutamatergic transmission in this region by group I 
mGluRs may play an important role in regulating generalized anxiety states. 
It is interesting to note that cocaine self administration has recently been reported 
to enhance AMPA/NMDA response ratios in the ventral BNST (Dumont et al., 2005), 
and intraperitoneal administration of cocaine enhances this ratio on dopaminergic 
neurons within the VTA (Borgland et al., 2004), a major efferent site from the BNST.  
Our data provide a potential mechanism contributing to these changes, as a reduction in 
the inhibitory constraint provided by group I mGluRs, as we have demonstrated, would 
likely facilitate the induction of NMDA-receptor dependent synaptic plasticity in these 
regions. 
 
Conclusions 
Our data, showing a lack of LTD in the BNST in ERK1 mutants and after 
pharmacological blockade of MEK, establish a critical role for this isoform in regulating 
synaptic function. Moreover, the recent idea that neural adaptations to drugs of abuse 
may involve the same molecular elements as those essential to behavioral plasticity is 
strongly confirmed by our results, as mGluR5-dependent LTD is greatly attenuated in 
animals self-administrating cocaine. These data suggest the possibility that 
hyperphosphorylation of ERK1 in the BNST (Valjent et al., 2004) in response to cocaine 
may be downstream of mGluR5 activation.  Interestingly, the mGluR LTD phenotype 
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seen in the BNST following cocaine administration resembles that found in a NAc upon 
repeated cocaine administration and is believed to be a crucial molecular substrate for 
long-term adaptations to drug abuse (Swanson et al., 2001; Fourgeaud et al., 2004). 
Future work with in vivo pharmacological blockade of ERK activation during cocaine 
administration will certainly help to elucidate the still largely obscure signaling 
mechanisms underlying the synaptic plasticity and pathophysiology of drug addiction 
involving the BNST. 
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CHAPTER V 
 
GENERAL DISCUSSION 
 
The integration of information from neurocircuits innervating the reward circuitry 
is becoming increasingly recognized.  For instance, the roles of stress/anxiety pathways 
in modulating specific effects of the reward system are becoming more apparent.  
Behavioral data suggests the BNST is involved in integrating stress information and 
relaying this information to the stress and reward pathways.  Moreover, behavioral data 
suggests glutamatergic transmission in the BNST as well as other regions in the 
stress/reward pathways plays an integral role in regulating stress and drug addiction 
behaviors. Synaptic plasticity in this region could in part underlie the persistent 
behavioral alterations in generalized anxiety and addiction.  However, little physiological 
(functional) data has been generated discerning the signaling pathways involved in BNST 
synaptic plasticity.  Utilizing electrophysiological techniques and incorporating 
pharmacological, biophysical, genetic and behavioral manipulations this thesis has been 
aimed at elucidating synaptic signaling pathways potentially involved in complex 
behaviors such as drug addiction in the BNST.   
 
Function of Group II MGluRs in Excitatory Transmission in the BNST 
The data I describe in this document suggest excitatory drive to the BNST, 
whether originating from the Ventral Subiculum, limbic cortex or the BLA, is modulated 
presynaptically by group II mGluRs.  Consistent with the function of group II mGluRs in 
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other brain regions (Bushell et al., 1996; Macek et al., 1996; Kilbride et al., 1998), we 
find selective activation of group II mGluRs in the BNST can produce a reversible 
depression of synaptic transmission. In other brain regions, group II mGluRs act as 
autoreceptors at glutamatergic synapses which, upon activation, results in a reduction in 
the probability of synaptic vesicle release.  Likewise, experiments designed to test for 
changes in release probability, PPR analysis, indicate a decrease in the probability of 
vesicular release following prolonged group II receptor activation in the BNST.   
There are many potential targets downstream of mGluR2/3 receptor activation.  
As would be expected of PTX sensitive Gαi-mediated effects, group II mGluRs have been 
shown to regulate adenylyl cyclase activity (Gereau and Conn, 1994), modulate ion 
channels, and in some cases activate PLC and PLD (Otani et al., 2002).  Other potential 
downstream targets implicated in vesicular release are the VGCCs.  Modulation of these 
channels located at the presynaptic terminals can reduce influx of calcium ultimately 
resulting in a decrease in vesicular release probability.  Future studies investigating the 
downstream effectors of group II mGluRs in the BNST such as PKA, PLC, PLD and 
VGCCs could prove beneficial in determining how these signaling pathways are involved 
in modulating vesicular release probability in the BNST. 
Interestingly, prolonged activation of group II mGluRs resulted in LTD while a 
brief activation of these receptors resulted in a short term, reversible depression.  It is 
conceivable that these receptors in the BNST undergo prolonged activation during 
extended periods of stress/anxiety and therefore could be targets for anxiolytics.  
Consistent with this, behavioral studies, both in rodent models of anxiety (Helton et al., 
1998; Klodzinska et al., 1999; Linden et al., 2002; Tizzano et al., 2002; Linden et al., 
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2003) and in humans (Fitzjohn et al., 1998; Grillon et al., 2003) suggest that group II and 
III mGluR ligands when given systemically may represent useful approaches to treat 
anxiety.   
. 
Function of Group III MGluRs in Excitatory Transmission in the BNST 
We found a persistent depression of synaptic transmission in studies in which the 
group III mGluR agonist L -AP4 was added.  This effect is likely mediated by the 
mGluR7 and/or 8 subtypes, as L -AP4 has an much higher affinity for mGluR4 than 7 and 
in the BNST a relatively high concentration of L-AP4 is required to produce significant 
weakening of excitatory transmission.  Also, the specific mGluR8 agonist DCPG 
produces a depression of EPSCs implicating a role for this receptor in the BNST.  
Consistent with this, anatomical evidence points to the expression of mGluR7, with 
weaker, if any, expression of mGluR4 in dBNST (Kinzie et al., 1995; Ohishi et al., 1995; 
Kinoshita et al., 1998). However, significant effects were observed with low 
concentrations of L-AP4, suggesting the possible involvement of mGLuR4 as well. Also 
consistent with anatomical data showing mGluR7 at the axon terminal, we find the 
functional output, as assessed by PPR, is a result of a reduced vesicular release 
probability. 
 
Implications for Group II and III MGluR Activation in the BNST 
While direct activation of group II and/or III mGluRs in the BNST has not been 
studied in vivo, other behavioral studies in which the AMPA receptor antagonist (NBQX) 
was injected into the BNST and global administration of mGluR agonists/antagonists can 
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give us insight into the behavioral consequences of group II and III mGluR function in 
the BNST.  One can speculate that as activation of these receptors function to decrease 
synaptic efficacy in this region, a decrease in the functional output of the BNST would be 
observed.  In other words, as antagonism of AMPARs results in the complete blockade of 
output from the BNST, the modulatory effect of reducing this output could have a similar 
result although perhaps less severe.  Future experiments designed to specifically target 
group II or III mGluRs in the BNST could provide insight into the legitimacy of this 
prediction.  For instance, one could knock down these receptors in the BNST using 
virally mediated methods followed by behavioral paradigms designed to test for 
anxiolytic states.     
It is difficult to make clear predictions regarding the net effect of group II and III 
activation in the BNST on propagation of a signal through the stress and reward 
circuitries.  However, one could speculate that reduced glutamatergic drive within the 
BNST would likely decrease output to the stress and reward circuitry, potentially 
reducing recruitment of the HPA axis (Figure 22). Therefore, as many pathophysiological 
disorders/syndromes have been linked to altered mGluR function, including 
stress/anxiety and drug addiction, mGluRs in the BNST, could be the targets of the 
anxiolytic effects of the group II and III compounds.  (Kim and Vezina, 1999; Kim et al., 
2005). 
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Figure 22.  Schematic showing potential effects of anxiolytic and anxiogenic stimuli on 
stress/anxiety pathway. 
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Group I MGluR Activation Weakens Excitatory Transmission in the BNST 
 Group I mGluRs have been shown to function at many synapses in the CNS.  As 
was the case in the BNST, a major function of group I mGluR activation is to produce a 
persistent weakening of glutamatergic transmission.  We investigate the synaptic locus as 
well as downstream effectors of group I mGluRs in the BNST.  Specifically, the role of 
CB1 receptor function and ERK in group I mGluR LTD were investigated.  In many 
ways the results we observed mapped onto the results of multiple labs studying group I 
mGluR function in the hippocampus (Huber et al., 2000; Huber et al., 2001; Snyder et al., 
2001; Nosyreva and Huber, 2005).   
 
Cannabinoids and Group I MGluRs 
 As suggested previously, there appear to be at least two major mechanisms 
through which group I mGluR LTD is accomplished.  One involves the recruitment of 
endocannabinoid signaling and presynaptic alterations, and has been observed in the 
dorsal and ventral striatum (Gerdeman and Lovinger, 2001; Sung et al., 2001; Robbe et 
al., 2002). A second major mechanism is through endocannabinoid-independent signaling 
mechanisms (Rouach and Nicoll, 2003), and has been extensively characterized in the 
hippocampus.  Consistent with PPR and mEPSC data, the early component of the DHPG 
mediated LTD was CB1R dependent.  However, the lasting depression was still present 
in the CB1R KO.  It is important to note that group I mGluR function in the BNST could 
be dependent on the retrograde signaling of CB’s.  For instance, in the hippocampus, 
group I mGluR mediated LTD of inhibitory transmission is dependent on CB1R signaling 
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(Chevaleyre and Castillo, 2003, 2004).  Future studies of CB signaling in the BNST 
could lead to new discoveries of the role of CB’s in stress/anxiety and drug addiction.  
 
The Role of ERK in Group I MGluR LTD  
As mentioned previously, much emphasis has been placed on the role of the 
MAPK/ERK signaling cascade in learning and memory, and in glutamatergic synaptic 
plasticity at a variety of synapses  (Orban et al., 1999; Adams et al., 2000; Mazzucchelli 
and Brambilla, 2000; Adams and Sweatt, 2002; Mazzucchelli et al., 2002; Gallagher et 
al., 2004; Sweatt, 2004).  It is not surprising then that this pathway has been implicated in 
drug addiction as well as indicated by recent work from the Caboche laboratory (Valjent 
et al., 2000; Valjent et al., 2004; Lu et al., 2005; Valjent et al., 2005).   
 In this body of work we present the first evidence that ERK1 rather than ERK2 
plays a critical role in neuronal function.  More specifically, that mGluR5-induced LTD 
in the BNST is dependent on ERK1.  At present, very little is known about the distinctive 
roles of the ERK1 and ERK2 isoforms, as they are highly homologous (Chen et al., 
2001).  However, several studies, primarily in non-neuronal systems, have identified 
proteins and/or drugs that produce or facilitate selective activation of ERK1 versus 
ERK2.  For example, MEK-binding partner 1 (MP1) selectively facilitates ERK1 
activation and binds with considerable selectivity to ERK1 over ERK2 (Schaeffer et al., 
1998).  While little information exists for substrates differentially phosphorylated by 
ERK1 and ERK2, data from knockout mice point to differences in function.  For 
example, while ERK1 knockout mice are viable and fertile (Pages et al., 1999; Selcher et 
al., 2001; Pages and Pouyssegur, 2004), targeted disruption of ERK2 produces a lethal 
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mutation (Adams and Sweatt, 2002).  Further, while much pharmacological evidence 
suggests that the MAP kinase signaling cascade plays an important role in NMDA-
receptor dependent synaptic plasticity and learning and memory, hippocampal and 
amygdala based learning are unimpaired in ERK1 knockout mice (Selcher et al., 2001), 
and NMDA receptor dependent plasticity is either normal (Selcher et al., 2001), or altered 
in complex ways in ERK1 null mice (Mazzucchelli et al., 2002).  Thus in future studies it 
will be important to determine why ERK1 is specifically required for DHPG-induced 
LTD in the BNST, and to determine whether this is a broader feature of mGluR5-
dependent regulation of transmission, or whether it is specific to restricted regions like 
the BNST. 
 
Downstream of ERK in Group I MGluR LTD 
In neurons, ERK activation has been shown to be involved in learning based 
remodeling of dendritic synapses, interactions with dendritic spine stabilizing proteins, 
interaction with scaffolding proteins and regulation of protein synthesis (Sweatt, 2004).  
In the hippocampus, group I mGluR-induced LTD is dependent on dendritic protein 
synthesis (Huber et al., 2000; Huber et al., 2001; Gallagher et al., 2004) and results in 
alterations in protein synthesis dependent AMPA receptor trafficking (Mangiavacchi and 
Wolf, 2004; Nosyreva and Huber, 2005; Xiao et al., 2001; (Snyder et al., 2001; 
Collingridge et al., 2004).  As group I mGluR LTD in the BNST is dependent on ERK 
activation, we investigated the possibility that this LTD is protein synthesis dependent 
and dependent on AMPA receptor trafficking. However, neither of two chemically  
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Figure 23.  DHPG-induced LTD is unchanged by preincubation with the mechanistically 
distinct protein synthesis inhibitors Anisomycin or Cycloheximide. 
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distinct protein synthesis inhibitors altered group I mGluR LTD in the BNST (Figure 23).  
This suggests, unlike the group I mGluR-mediated LTD reported by Huber and 
colleagues and under the conditions of these recordings, protein synthesis is not involved 
in group I mGluR LTD in the BNST.  However, we cannot rule out the possibility of a 
role for protein synthesis in group I mGluR-mediated LTD in the BNST as there is not a 
good positive control for this data. 
AMPAR internalization is emerging as a major mechanism for synaptic 
depression as was emphasized in the introduction.  AMPAR internalization is dependent 
on the clathrin-mediated pathway involving the GTPase dynamin (Cremona and De 
Camilli, 1997; Collingridge et al., 2004), and is enhanced by factors that can induce 
synaptic depression, such as NMDAR stimulation (Beattie et al., 2000; Ehlers, 2000; Lin 
et al., 2000; Man et al., 2000; Man et al., 2000).  Group I mGluR activation has been 
shown to be enhance endocytosis as well (Mundell et al., 2001; Snyder et al., 2001; Xiao 
et al., 2001; Kawasaki et al., 2004).   
To begin to investigate a role for endocytosis we studied the effects of 
intracellular Jasplakinolide on the group I mGluR-mediated LTD in the BNST.  
Jasplakinolide is a toxin that acts as to stabilize actin and therefore disrupts endocytosis.  
Results in hippocampal slices indicate this drug is sufficient to prevent DHPG induced 
LTD (Xiao et al., 2001).  In 4 of 5 experiments in which Jasplakinolide was introduced 
into postsynaptic BNST neurons group I mGluR-mediated LTD was greatly attenuated 
(Figure 24).  Future studies introducing the dynamin-amphiphysin inhibitory peptide, 
which has been shown to block endocytosis, into the postsynaptic cell will help determine 
if endocytosis is involved in maintaining group I mGluR LTD in the BNST.  A positive 
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result from these experiments will then lead us to test if GluR2 or perhaps mGluR5 are 
being endocytosed following activation of group I mGluRs.  More specifically, we will 
begin to test for a role of the specific AMPAR subunits in group I mGluR-mediated LTD 
in the BNST. 
As trafficking of the GluR1 subunit of the AMPAR may be a target for 
maintenance of group I mGluR LTD we tested the effects of DHPG on EPSC amplitude 
in BNST neurons from GluR1 knockout mice.  In the GluR1 knockout mouse, the 
number of synaptic AMPARs is normal but the extrasynaptic receptors are greatly 
diminished (Zamanillo et al., 1999).  Utilizing the GluR1 KO mice we investigated the 
role of GluR1 in group I mGluR LTD in the BNST.  There is no change in DHPG-
induced LTD in the BNST neurons from GluR1 KO mice suggesting this AMPAR 
subunit is not critical for this form of LTD (Figure 24).  However, it is still possible that 
GluR2 containing AMPA receptors are involved in DHPG-induced LTD and therefore 
experiments designed to inhibit GluR2 trafficking or utilizing GluR2 knockout mice 
would be beneficial.   
 
Group I MGluR LTD of Excitatory Synaptic Transmission is Attenuated in the BNST 
from Animals that Self-Administered Cocaine  
 
 A number of labs have shown that group I mGluRs play key roles in behavioral 
responses to psychostimulants.  Genetic disruption of either mGluR5 (Chiamulera et al., 
2001) or the homer family of group I mGluR interacting proteins (Swanson et al., 2001) 
produces profound alterations in responses to psychostimulants, as does pharmacological 
inhibition of group I mGluRs (McGeehan and Olive, 2003; Herzig and Schmidt, 2004).   
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Figure 24.  a.  DHPG-induced LTD in the BNST is independent of GluR1.  b.  The actin 
stabilizing compound Jasplakinolide alters postsynaptic induced LTD (30 min post 
DHPG) in 4 of 5  BNST neurons. 
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A potential explanation for the attenuation of mGluR5-mediated LTD observed in the 
BNST following cocaine administration could potentially be downregulation of mGluR5 
or perhaps disruption of mGluR5 mediated effects due to changes in scaffolding 
complexes involving Homer proteins. 
Interestingly, it has been shown that puffing of glutamate into the BNST results in an 
increase in DA neuron firing in the VTA (Georges and Aston-Jones, 2002).  However, 
upon greater stimulation of the BNST by glutamate, there is a blockade of VTA DA 
neuron firing (Georges and Aston-Jones, 2002).  As activation of group I mGluRs in the 
BNST results in a decrease in BNST output, it is possible that this acts to prevent the 
switch from increased firing to no firing of VTA neurons.  This could therefore explain 
the lack of a cocaine self-administration phenotype in mGluR5 knockouts and in 
experiments where mGluR5 signaling is blocked. 
As mentioned in the introduction, remodeling of dendrites, axons, and synapses 
are proposed mechanisms for drug-induced changes in neuronal signaling.  These 
changes could ultimately lead to changes in synaptic strength, generation of new 
synapses, or silencing of existing synapses and, thus, to the reorganization of circuits 
(Sala et al., 2001).  Such long lasting changes are potentially due to drug-induced 
alteration in gene expression or in protein translation. Although under the experimental 
parameters used in the study of protein synthesis dependence of mGluR LTD we did not 
find any effect, it is still possible that in vivo, mGluR5 activity may lead to changes in 
gene expression and ultimately protein synthesis.   
This thesis has revolved around laying the groundwork to study the phenomena of 
drug-induced changes in neuronal signaling in the BNST.  Future directions looking at 
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changes in mGluR5 function, changes in AMPAR subunit expression and ERK pathway 
desensitization in the BNST could elucidate the correlation between the mechanism and 
behavioral changes induced by cocaine and other drugs of abuse.  For instance, as is 
speculated with the homer2 KOs, it is possible that attenuated mGluR5 LTD in the BNST 
may be due to desensitization of mGluR5 (Sala et al., 2001).  Another possibility is 
downregulation of AMPAR expression as well as a disconnection of the proposed 
mGluR5/AMPAR interaction.  Downregulation of AMPARs following cocaine treatment 
would suggest a cocaine-induced LTD of EPSCs that would, in turn, occlude the group I 
mGluR-mediated LTD.   
 
Implications for Group I MGluR Function in the BNST on Stress/Anxiety  
 
Lesioning the lateral BNST results in decreased CRH mRNA in the PVN and also 
decreased plasma corticosterone levels, which directly regulated by the PVN (Dunn, 
1987; Herman et al., 1994).  Decreased HPA output suggests that under basal conditions, 
activation of the PVN is consequent to activation of the lateral BNST.  Therefore, a 
reduction in excitatory drive via mGluR activation could result in a reduction in PVN 
activation which ultimately results in an anxiolytic phenotype.  This is consistent with the 
behavioral data suggesting anxiolytic properties of group II and III agonists (Fitzjohn et 
al., 1998) however contradicts the anxiolytic properties reported from group I mGluR 
antagonists (Pilc et al., 2002).  However, to illustrate the complexity of the BNST 
circuitry, Dunn et al found that electrical stimulation of the lateral BNST resulted in a 
decrease while stimulation of the medial BNST caused an increase in plasma 
corticosterone levels (Dunn, 1987).  This would be consistent with the group I mGluR 
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antagonists could acting as an anxiolytic like compound at the level of synapses onto the 
BNST yet contradicts the group II and III agonist effects. 
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